API




KE Relationships

Navigational tip: click on "leads to" or the ID column to navigate to the KE Relationship.
Id Upstream Event Relationship Type Downstream Event
1330 Binding, topoisomerase II leads to MLL translocation
1635 DSB leads to MLL translocation
305 TH synthesis, Decreased leads to T4 in serum, Decreased
366 Thyroperoxidase, Inhibition leads to T4 in serum, Decreased
443 Thyroidal Iodide, Decreased leads to T4 in serum, Decreased
1493 CYP7B activity, inhibition leads to 7α-hydroxypregnenolone synthesis in the brain, decreased
348 BDNF, Reduced leads to Aberrant, Dendritic morphology
568 Increased, Appetite and hunger leads to Abnormal, Foraging activity and behavior
575 Increased, Viral susceptibility leads to Abnormal, Foraging activity and behavior
583 Impairment, Learning and memory leads to Abnormal, Foraging activity and behavior
1147 Activation, Nicotinic acetylcholine receptor leads to Abnormal, Foraging activity and behavior
1157 Increased, Energetic demands and therefore metabolic stress leads to Abnormal, Foraging activity and behavior
329 Insufficiency, Vascular leads to Abnormal, Morphogenesis
1150 Abnormal, Foraging activity and behavior leads to Abnormal, Role change within caste
564 Impairment, Learning and memory leads to Abnormal, Roll change within caste
578 Reduced, Antiseptic incorporated in food leads to Abnormal, Roll change within caste
1148 Abnormal, Foraging activity and behavior leads to Abnormal, Roll change within caste
662 Accumulation, Damaged mitochondrial DNA leads to Accelerated, Aging
11 Inhibition, Acetylcholinesterase (AchE) leads to Accumulation, Acetylcholine in synapses
295 Activation, Stellate cells leads to Accumulation, Collagen
303 Up Regulation, TGFbeta1 expression leads to Accumulation, Collagen
1628 Collagen Deposition leads to Accumulation, Collagen
1654 Differentiation of fibroblasts leads to Accumulation, Collagen
1655 EMT leads to Accumulation, Collagen
661 Overwhelmed, Mitochondrial DNA repair mechanisms leads to Accumulation, Damaged mitochondrial DNA
190 Decreased, Mitochondrial fatty acid beta-oxidation leads to Accumulation, Fatty acid
475 Inhibition, Mitochondrial fatty acid beta-oxidation leads to Accumulation, Fatty acid
503 Decreased, PCK1 expression (control point for glycolysis/gluconeogenesis pathway) leads to Accumulation, Fatty acid
505 Increased, FA Influx leads to Accumulation, Fatty acid
508 Increased, LDL uptake leads to Accumulation, Fatty acid
512 Increased, De Novo FA synthesis leads to Accumulation, Fatty acid
1660 Decreased, Ketogenesis leads to Accumulation, Fatty acid
864 Oxidation, Uroporphyrinogen leads to Accumulation, Highly carboxylated porphyrins
1070 Inhibition, UROD leads to Accumulation, Highly carboxylated porphyrins
470 Inhibition, Mitochondrial fatty acid beta-oxidation leads to Accumulation, Liver lipid
471 Suppression, VLDL secretion leads to Accumulation, Liver lipid
474 Accumulation, Triglyceride leads to Accumulation, Liver lipid
502 Accumulation, Fatty acid leads to Accumulation, Liver lipid
110 Synthesis, De Novo FA leads to Accumulation, Triglyceride
132 Increase, FA Influx leads to Accumulation, Triglyceride
472 Accumulation, Fatty acid leads to Accumulation, Triglyceride
504 Increased, FA Influx leads to Accumulation, Triglyceride
1657 Up Regulation, SCD-1 leads to Accumulation, Triglyceride
1441 Increase, intracellular calcium leads to Activate, calmodulin
1462 Increase, GABA leads to Activate, GABA-A receptor
1463 Increased, RDX dose leads to Activate, GABA-A receptor
1477 Increase, leukocyte adherence leads to Activate, leukocyte
1484 Increase, bicarbonate leads to Activate, mucosal defense
1485 Increase, mucous leads to Activate, mucosal defense
1486 Increase, mucosal blood flow leads to Activate, mucosal defense
1489 Increase, surfactant leads to Activate, mucosal defense
1438 Activation, 5-HT2A leads to Activate, PLC
1476 Activate, leukocyte leads to Activated, gastric ulcer formation
1533 Reduced, platelet aggregation leads to Activated, gastric ulcer formation
1536 Reduced, mucosal defense leads to Activated, gastric ulcer formation
1542 Decreased, angiogenesis leads to Activated, gastric ulcer formation
1545 Increased, leukocyte activation leads to Activated, gastric ulcer formation
1558 Reduced, SHP activity leads to Activated, LXR
1457 Activated, voltage-gated sodium channel leads to Activated, membrane depolarization
1554 Decreased, intracellular chloride leads to Activated, membrane depolarization
1453 Increased, glutamate leads to Activated, NMDA receptor
1455 Increased, intracellular sodium (Na+) leads to Activated, voltage-gated sodium channel
1608 demethylation, PPARg promoter leads to Activation of specific nuclear receptors, PPAR-gamma activation
1610 activation of CEBPA leads to Activation of specific nuclear receptors, PPAR-gamma activation
248 Bile accumulation, Pathological condition leads to Activation of specific nuclear receptors, Transcriptional change
1353 Inactivation of PPARγ leads to Activation of TGF-β signaling
1374 Glutathione synthesis leads to Activation, 3-hydroxy-3-methylglutaryl-CoA reductase gene
1437 Decreased, extracellular serotonin leads to Activation, 5-HT2A
1531 Increased, extracellular serotonin leads to Activation, 5-HT2A
1392 Activation, mTORC2 leads to Activation, AKT
1418 Activation, PI3K leads to Activation, AKT
541 inflammation leads to Activation, AKT2
1420 Activation, PI3K leads to Activation, aPKC
174 Activation, LXR leads to Activation, ChREBP
377 Covalent Binding, Protein leads to Activation, Dendritic Cells
378 Response, Keratinocytes leads to Activation, Dendritic Cells
834 Activation, Keratinocytes leads to Activation, Dendritic Cells
1699 Activation, Inflammatory cytokines, chemokines, cytoprotective gene pathways leads to Activation, Dendritic Cells
1700 N/A, Covalent binding to protein, possibly lysine residue leads to Activation, Dendritic Cells
1102 prepubertal increase, Estrogen receptor (ER) activity leads to Activation, estrogen receptor alpha
175 Activation, LXR leads to Activation, FAS
1424 demethylation, PPARg promoter leads to Activation, FAS
1425 Activation, LRH-1 leads to Activation, FAS
1380 Activation, JNK leads to Activation, FOXO
1397 Activation, SREBP-1 leads to Activation, FXR
1406 Activation, NRF2 leads to Activation, FXR
1450 Increase, cortisone leads to Activation, Glucocorticoid Receptor
1364 Increase, Oxidative Stress / Activation, PMK-1 P38 MAPK leads to Activation, HIF-1
1396 Activation, mTORC1 leads to Activation, HSD17B4
1410 Activation, PPARα leads to Activation, HSD17B4
88 N/A, Covalent binding to protein, possibly lysine residue leads to Activation, Inflammatory cytokines, chemokines, cytoprotective gene pathways
1390 Increase, insulin leads to Activation, insulin receptor
1379 Peptide Oxidation leads to Activation, JNK
833 Covalent Binding, Protein leads to Activation, Keratinocytes
1395 Activation, mTORC1 leads to Activation, L-FABP
1400 Activation, AKT leads to Activation, L-FABP
1419 Activation, PI3K leads to Activation, L-FABP
476 Suppression, Constitutive androstane receptor, NR1l3 leads to Activation, LXR
535 Activation, PPARα leads to Activation, LXR alpha
1393 Activation, mTORC2 leads to Activation, mTORC1
1398 Activation, AKT leads to Activation, mTORC1
1391 Activation, insulin receptor leads to Activation, mTORC2
1236 Activation, PPARα leads to Activation, NADPH Oxidase
532 Activation, NRF2 leads to Activation, NR1H4
534 Activation, NR1H4 leads to Activation, PPARα
1408 Activation, FXR leads to Activation, PPARα
1409 Activation, SHP leads to Activation, PPARα
176 Activation, LXR leads to Activation, SCD-1
1403 Activation, SREBP-1 leads to Activation, SCD-1
533 Activation, NR1H4 leads to Activation, SHP
1407 Activation, FXR leads to Activation, SHP
946 Activation, Epidermal Growth Factor Receptor leads to Activation, Sp1
964 Activation, EGFR leads to Activation, Sp1
479 Activation, LXR leads to Activation, SREBF1
487 demethylation, PPARg promoter leads to Activation, SREBF1
1661 Activation, AKT2 leads to Activation, SREBF1
1394 Activation, AKT leads to Activation, SREBP-1
1399 Activation, mTORC1 leads to Activation, SREBP-1
1402 demethylation, PPARg promoter leads to Activation, SREBP-1
1421 Activation, aPKC leads to Activation, SREBP-1
177 Activation, LXR leads to Activation, SREBP-1c
68 N/A, Cell injury/death leads to Activation, Stellate cells
304 Up Regulation, TGFbeta1 expression leads to Activation, Stellate cells
1764 Increased pro-inflammatory mediators leads to Activation, Stellate cells
1778 Leukocyte recruitment/activation leads to Activation, Stellate cells
1015 Inhibition, Calcineurin Activity leads to Activation, Suppression of NFAT activation and hindrance of nuclear localization
1369 Activation, JAK/STAT pathway leads to Activation, TGF-beta pathway
1651 TGFbeta1 activation leads to TGFbeta pathway activation
379 Activation, Dendritic Cells leads to Activation/Proliferation, T-cells
380 Response, Keratinocytes leads to Activation/Proliferation, T-cells
1265 Decline, Population leads to Alteration, Food-web structures
1097 Increased, PPAR-alpha activation leads to Alteration, lipid metabolism
35 N/A, Androgen receptor, Antagonism leads to Alteration, Wnt pathway
317 Decreased, Transcription of genes by AR leads to Alteration, Wnt pathway
875 Activation, Long term AHR receptor driven direct and indirect gene expression changes leads to Alterations, Cellular proliferation / hyperplasia
996 N/A, Hepatotoxicity, Hepatopathy, including a constellation of observable effects leads to Alterations, Cellular proliferation / hyperplasia
1268 Activation, Constitutive androstane receptor leads to Altered expression of hepatic CAR-dependent genes
18 Activation, AhR leads to Altered regulation, AHR nuclear translocator (ARNT)-dependent pathways
242 N/A, Parent compound is converted to the reactive metabolite and forms free radicals leadin leads to Altered regulation, Alpha hemoglobin
1767 Inhibition, Aromatase leads to Altered regulation, Alpha hemoglobin
701 impaired, ion channels leads to Altered, Action Potential
1142 Decreased, Thyroxine (T4) in tissues leads to Altered, Amphibian metamorphosis
1164 Decreased, Triiodothyronine (T3) in tissues leads to Altered, Amphibian metamorphosis
1201 Increased, Triiodothyronine (T3) in tissues leads to Altered, Amphibian metamorphosis
1309 Desensitization, Nicotinic acetylcholine receptor leads to Altered, Ca2+-calmodulin activated signal transduction
1311 N/A, Mitochondrial dysfunction 1 leads to Altered, Ca2+-calmodulin activated signal transduction
16 Altered regulation, AHR nuclear translocator (ARNT)-dependent pathways leads to Altered, Cardiovascular development/function
976 Impairment, Endothelial network leads to Altered, Cardiovascular development/function
1351 Increase, COX-2 expression leads to Altered, Cardiovascular development/function
724 Binding, Tubulin leads to Altered, Chromosome number
738 Altered, Meiotic chromosome dynamics leads to Altered, Chromosome number
1296 Increased, ER binding to DNA (classical pathway) leads to Altered, Gene Expression
1297 Increased, ER binding to T.F. to DNA (non-classical pathway) leads to Altered, Gene Expression
1301 Increase, DNA Damage leads to Altered, Gene Expression
1302 Increased, Non-genomic signaling leads to Altered, Gene Expression
280 Increase, Renal pathology due to VTG deposition leads to Altered, Larval development
737 Disorganization, Spindle leads to Altered, Meiotic chromosome dynamics
203 Altered, Neuroanatomy leads to Altered, Neurophysiology
1298 Altered, Gene Expression leads to Altered, Protein Production
126 Agonism, Estrogen receptor leads to Altered, Reproductive behaviour
1566 hyperpolarisation, neuron leads to Analgesia
1570 Inhibition of neurotransmitter release leads to Analgesia
1572 hyperpolarisation, neuron leads to Anti-depressant Activity
1573 Inhibition of neurotransmitter release leads to Anti-depressant Activity
1341 Mitochondrial impairment leads to Apoptosis
1365 Activation, HIF-1 leads to Apoptosis
1366 Increased, DNA Damage-Repair leads to Apoptosis
1367 Damaging, Mitochondria leads to Apoptosis
1712 cell cycle, disrupted leads to Apoptosis
1716 Histone deacetylase inhibition leads to Apoptosis
927 Inhibition, Bile Salt Export Pump (ABCB11) leads to Bile accumulation, Pathological condition
332 Production, VEGF-A leads to Binding, VEGF-A
1169 Failure in vascular repair mechanisms, Unresolved blood loss (hemorrhage) leads to Blood loss and development of anemia, Impaired oxygen delivery and nutrient delivery to tis
1194 Anticoagulant rodenticide interferes with gamma-carboxyglutamate formation, Inhibition of p leads to Calcium cannot bind to the hydroxyapatite matrix of bone, Osteocalcin and other bone protei
1711 p21 (CDKN1A) expression, increase leads to cell cycle, disrupted
1715 Histone deacetylase inhibition leads to cell cycle, disrupted
874 Activation, Long term AHR receptor driven direct and indirect gene expression changes leads to Changes/Inhibition, Cellular Homeostasis and Apoptosis
319 Activation of specific nuclear receptors, Transcriptional change leads to Cholestasis, Pathology
929 Increase, Inflammation leads to Cholestasis, Pathology
931 Production, Reactive oxygen species leads to Cholestasis, Pathology
932 Peptide Oxidation leads to Cholestasis, Pathology
1315 Increase, Mucin production leads to Chronic, Mucus hypersecretion
549 Increased, Induced Mutations in Critical Genes leads to Clonal Expansion/Cell Proliferation, to form Altered Hepatic Foci (AHF)
551 Formation, Pro-mutagenic DNA Adducts leads to Clonal Expansion/Cell Proliferation, to form Altered Hepatic Foci (AHF)
383 Thyroperoxidase, Inhibition leads to Cognitive Function, Decreased
384 Altered, Neurophysiology leads to Cognitive Function, Decreased
403 T4 in serum, Decreased leads to Cognitive Function, Decreased
748 Hippocampal Physiology, Altered leads to Cognitive Function, Decreased
1357 Expression of Collagen leads to Collagen Deposition
1779 EMT leads to Collagen Deposition
1273 Sensory Airway Irritation leads to Cough, Dyspnea, Sneezing, Acute respiratory effect
1275 Excitation, Trigeminal nerve excitation leads to Cough, Dyspnea, Sneezing, Acute respiratory effect
836 Inhibition, Phospholipase A leads to Damage, Lipid bilayer
321 Accumulation, Triglyceride leads to Damaging, Mitochondria
1363 Increase, Oxidative Stress / Activation, PMK-1 P38 MAPK leads to Damaging, Mitochondria
241 Propagation, Oxidative stress leads to Damaging, Red blood cells; hemolysis
245 N/A, Parent compound is converted to the reactive metabolite and forms free radicals leadin leads to Damaging, Red blood cells; hemolysis
559 Decrease, Number of worker bees leads to Death/Failure, Colony
563 impaired, Larval development leads to Death/Failure, Colony
574 impaired, Hive thermoregulation leads to Death/Failure, Colony
1145 Weakened, Colony leads to Death/Failure, Colony
135 Decrease, Fecundity leads to Decline, Population
199 Increase, Mortality leads to Decline, Population
200 Increased, Mortality leads to Decline, Population
1180 Decreased, Reproductive Success leads to Decline, Population
1184 Increase, predation leads to Decline, Population
1264 Increased, Male offspring leads to Decline, Population
870 BDNF, Reduced leads to GABAergic interneurons, Decreased
1505 TH synthesis, Decreased leads to GABAergic interneurons, Decreased
358 Synaptogenesis, Decreased leads to Neuronal network function, Decreased
368 N/A, Neurodegeneration leads to Neuronal network function, Decreased
582 N/A, Mitochondrial dysfunction 1 leads to Neuronal network function, Decreased
659 Desensitization, Nicotinic acetylcholine receptor leads to Neuronal network function, Decreased
1688 N/A, Cell injury/death leads to Neuronal network function, Decreased
1691 Glutamate dyshomeostasis leads to Neuronal network function, Decreased
355 N/A, Cell injury/death leads to Synaptogenesis, Decreased
356 Aberrant, Dendritic morphology leads to Synaptogenesis, Decreased
357 Reduced, Presynaptic release of glutamate leads to Synaptogenesis, Decreased
447 Delay, Developmental GABA shift leads to Synaptogenesis, Decreased
448 BDNF, Reduced leads to Synaptogenesis, Decreased
759 N/A, Neuroinflammation leads to Synaptogenesis, Decreased
871 GABAergic interneurons, Decreased leads to Synaptogenesis, Decreased
442 Inhibition, Na+/I- symporter (NIS) leads to Thyroidal Iodide, Decreased
1197 Inhibition, Iodotyrosine deiodinase (IYD) leads to Thyroidal Iodide, Decreased
1008 Decrease, Circulating ETH leads to Decrease, Abdominal muscle contraction
1349 Decrease, Excitatory postsynaptic potential leads to Decrease, Abdominal muscle contraction
936 Activation, Epidermal Growth Factor Receptor leads to Decrease, Apoptosis of ciliated epithelial cells
962 Activation, EGFR leads to Decrease, Apoptosis of ciliated epithelial cells
256 demethylation, PPARg promoter leads to Decrease, Aromatase (Cyp19a1)
792 Inhibition, 5α-reductase activity leads to Decrease, Bioactivation of testosterone
1756 Decrease, Calcium currents leads to Decrease, Calcium binding to Troponin C
1755 Blockade, L-Type Calcium Channels leads to Decrease, Calcium currents
1757 Decrease, Calcium binding to Troponin C leads to Decrease, Cardiac contractility
1762 Disruption, Sarcomere assembly leads to Decrease, Cardiac contractility
1758 Decrease, Cardiac contractility leads to Decrease, Cardiac ejection fraction
1664 Decrease, Chloroplast ATP production leads to Decrease, Chlorophyll synthesis
1663 Increase, Uncoupling of photophosphorylation leads to Decrease, Chloroplast ATP production
1346 Decrease, Circulating ETH leads to Decrease, Circulating CCAP
998 Increase, EcR agonism leads to Decrease, Circulating ETH
1345 Increase, Ftz-f1 expression leads to Decrease, Circulating ETH
1742 Increase, CHS inhibition leads to Decrease, Cuticular chitin synthesis
1747 Increase, Opening of voltage-dependent calcium channel leads to Decrease, Cuticular chitin synthesis
1417 Induction, fatty acid beta-oxidation leads to Decrease, cytosolic fatty acid
1085 Decreased, Ovarian E2 leads to Decrease, E2 blood concentrations at hypothalamus
1086 Suppression, Estrogen receptor (ER) activity leads to Decrease, E2 blood concentrations at hypothalamus
1347 Decrease, Circulating CCAP leads to Decrease, Ecdysis motoneuron bursts
1348 Decrease, Ecdysis motoneuron bursts leads to Decrease, Excitatory postsynaptic potential
198 Increase, Mortality leads to Decrease, Fecundity
261 Induction, Pre-mature molting leads to Decrease, Fecundity
1752 Decrease, Oogenesis leads to Decrease, Fecundity
1753 Decrease, Ovulation leads to Decrease, Fecundity
393 irregularities, ovarian cycle leads to Decrease, Fertility
808 malformed, Male reproductive tract leads to Decrease, Fertility
1471 Decrease, Ovulation leads to Decrease, Fertility
1667 Decrease, Photosynthesis leads to Decrease, Glycolysis
1739 Decrease, Mitochondrial ATP production leads to Growth
1741 Increase, Apoptosis leads to Growth
1061 Antagonism, Histamine Receptor (H2) leads to Decrease, histaminergic neuron excitation
790 Thyroperoxidase, Inhibition leads to Decrease, Incorporation of active iodide into iodotyrosines
1670 Decrease, Mitochondrial ATP production leads to Decrease, Leaf cell mitosis
1671 Decrease, Leaf cell mitosis leads to Decrease, Leaf development
1478 Activation, PTGS-2 leads to Decrease, leukocyte adherence
1665 Decrease, Chlorophyll synthesis leads to Decrease, Light harvest capacity
1314 Chronic, Mucus hypersecretion leads to Decrease, Lung function
188 Disruption, Mitochondrial electron transport chain leads to Decrease, Mitochondrial ATP production
1600 Increase, Uncoupling of OXPHOS leads to Decrease, Mitochondrial ATP production
1669 Decrease, OXPHOS leads to Decrease, Mitochondrial ATP production
1681 Dysfunction, Mitochondria leads to Decrease, Mitochondrial ATP production
1738 Decrease, Glycolysis leads to Decrease, Mitochondrial ATP production
558 Reduced, Food storage leads to Decrease, Number of worker bees
569 Abnormal, Foraging activity and behavior leads to Decrease, Number of worker bees
572 impaired, Development leads to Decrease, Number of worker bees
580 Abnormal, Roll change within caste leads to Decrease, Number of worker bees
663 Accelerated, Aging leads to Decrease, Number of worker bees
1469 Increase, Apoptosis leads to Decrease, Oogenesis
1597 Increase, Follicular atresia leads to Decrease, Oogenesis
1601 Decrease, Mitochondrial ATP production leads to Decrease, Oogenesis
685 Reduced, Prostaglandins, ovary leads to Decrease, Ovulation
1470 Decrease, Oogenesis leads to Decrease, Ovulation
1668 Decrease, Glycolysis leads to Decrease, OXPHOS
1666 Decrease, Light harvest capacity leads to Decrease, Photosynthesis
1737 PSII activity leads to Decrease, Photosynthesis
1736 D1 protein blockage leads to PSII activity
51 Induction, Ataxia, paralysis, or hyperactivity leads to Decrease, Population trajectory
94 Reduction, Cumulative fecundity and spawning leads to Decrease, Population trajectory
675 Reduced, Reproductive Success leads to Decrease, Population trajectory
1030 Reduced, Young of year survival leads to Decrease, Population trajectory
1472 Decrease, Fertility leads to Decrease, Population trajectory
768 Decreased, Uptake of inorganic iodide leads to Decrease, Serum thyroid hormone (T4/T3)
791 Decrease, Incorporation of active iodide into iodotyrosines leads to Decrease, Serum thyroid hormone (T4/T3)
369 Activation, PPARα leads to Decrease, Steroidogenic acute regulatory protein (STAR)
1487 Increase, ammonium (NH4+) leads to Decrease, surfactant
1488 Activate, phospholipase leads to Decrease, surfactant
370 Activation, PPARα leads to Decrease, Translocator protein (TSPO)
1615 decreased reward leads to decreased DNA methylation of tyrosine hydroxylase
1613 chronic high fat diet leads to decreased dopamine
1617 decreased reward leads to decreased dopamine
1620 decreased DNA methylation of tyrosine hydroxylase leads to decreased dopamine
1621 decreased methylation of dopamine transporter promoter leads to decreased dopamine
1616 decreased reward leads to decreased methylation of dopamine transporter promoter
1765 Binding, SH/SeH proteins involved in protection against oxidative stress leads to Protection against oxidative stress, decreased
1614 decreased dopamine leads to decreased reward
1649 Reduction, testosterone level leads to Decreased sperm quantity or quality in the adult, Decreased fertility
154 Decreased, HSD17B10 expression leads to Decreased, 3-hydroxyacyl-CoA dehydrogenase type-2 activity
1529 Increased, extracellular serotonin leads to Decreased, 5-HT3
1541 Reduced, PTGS2 function leads to Decreased, angiogenesis
644 Increased, serotonin (5-HT) leads to Decreased, anxiety
1304 Altered, Protein Production leads to Decreased, Apoptosis (Epithelial Cells)
800 Increased, HIF-1 heterodimer leads to Decreased, Aromatase (Cyp19a1) mRNA
1539 Reduced, PTGS1 function leads to Decreased, bicarbonate
1095 Increased, PPAR-alpha activation leads to Decreased, bile flow
885 Increased, Catabolism of Muscle Protein leads to Decreased, Body Weight
213 Inhibition, NMDARs leads to Decreased, Calcium influx
1245 Decreased, GABA release leads to Decreased, Chloride conductance
805 Decreased, mevalonate leads to Decreased, cholesterol
1009 Decreased, Synthesis of molting fluid proteases leads to Decreased, Digestion of old cuticle
1429 Decreased, serotonin transporter activity leads to Decreased, extracellular chloride (Cl-)
1434 Decreased, synaptic release leads to Decreased, extracellular serotonin
1521 Increased, extracellular serotonin leads to Decreased, extracellular serotonin
1528 Increased, serotonin transporter activity leads to Decreased, extracellular serotonin
1428 Decreased, serotonin transporter activity leads to Decreased, extracellular Na+
1551 Reduced, presynaptic neuron 2 activity leads to Decreased, GABA
1244 Decreased, sodium conductance 2 leads to Decreased, GABA release
1186 Increased, serotonin (5-HT) 1 leads to Decreased, gametogenesis
817 Occurrence, Cytoplasmic vacuolization (Renal tubule) leads to Decreased, Glomerular filtration
821 Occurrence, Cystic dilatation (renal tubule) leads to Decreased, Glomerular filtration
825 Occurrence, Cytoplasmic vacuolization (podocyte) leads to Decreased, Glomerular filtration
257 Decreased, PPAR-alpha activation leads to Decreased, HSD17B10 expression
259 Decreased, PPAR-beta activation leads to Decreased, HSD17B10 expression
260 Decreased, PPAR-gamma activation leads to Decreased, HSD17B10 expression
576 Decreased, Glucose oxidase enzyme activity leads to Decreased, Hydrogen peroxide production
1553 Reduced, GABA-A receptor activation leads to Decreased, intracellular chloride
1431 Decreased, serotonin transporter activity leads to Decreased, intracellular serotonin
1243 Decreased, sodium conductance 2 leads to Decreased, Ionotropic GABA receptor chloride channel conductance
524 Down Regulation, HMGCS2 leads to Decreased, Ketogenesis
880 Decreased, PPARalpha transactivation of gene expression leads to Decreased, Ketogenesis (production of ketone bodies)
882 Decreased, Mitochondrial Fatty Acid Beta Oxidation leads to Decreased, Ketogenesis (production of ketone bodies)
1749 Fatty Acid Beta Oxidation, Decreased leads to Decreased, Ketogenesis (production of ketone bodies)
1108 Decreased, GnRH pulsatility/release in hypothalamus leads to Decreased, LH Surge from anterior pituitary
650 N/A, sedation leads to Decreased, locomotion
1644 Impairment, Learning and memory leads to Decreased, locomotion
212 Decreased, Nitric Oxide leads to Decreased, Long-term potentiation (LTP)
388 Suppression, Inflammatory cytokines leads to Decreased, Lymphocytes
804 Inhibition, HMG-CoA reductase leads to Decreased, mevalonate
879 Decreased, PPARalpha transactivation of gene expression leads to Decreased, Mitochondrial Fatty Acid Beta Oxidation
881 Decreased, Peroxisomal Fatty Acid Beta Oxidation of Fatty Acids leads to Decreased, Mitochondrial Fatty Acid Beta Oxidation
9 Decreased, 3-hydroxyacyl-CoA dehydrogenase type-2 activity leads to Decreased, Mitochondrial fatty acid beta-oxidation
520 Down Regulation, CPT1A leads to Decreased, Mitochondrial fatty acid beta-oxidation
1534 Reduced, PTGS1 function leads to Decreased, mucosal blood flow
1537 Reduced, PTGS1 function leads to Decreased, mucous
647 N/A, Neurodegeneration leads to Decreased, Neuronal network function in adult brain
892 Increased, Intracellular Calcium overload leads to Decreased, Neuronal network function in adult brain
1447 Reduce expression, BDNF leads to Decreased, neuroplasticity
1523 Reduced, BDNF leads to Decreased, neuroplasticity
282 Increase, ROS production leads to Decreased, Nitric Oxide
1432 Decreased, intracellular serotonin leads to Decreased, packaged serotonin
499 Activation, AhR leads to Decreased, PCK1 expression (control point for glycolysis/gluconeogenesis pathway)
878 Decreased, PPARalpha transactivation of gene expression leads to Decreased, Peroxisomal Fatty Acid Beta Oxidation of Fatty Acids
756 Increased, Mortality leads to Decreased, population 1
1004 Increase, Mortality leads to Decreased, population 1
1013 Increase, Mortality leads to Decreased, Population size
1191 Increased, Mortality leads to Decreased, Population size
428 Increased, Mortality leads to Decreased, Population trajectory
453 Inhibition, Acetylcholinesterase (AchE) leads to Decreased, Population trajectory
1501 Decreased, Reproductive Success leads to Decreased, Population trajectory
877 Binding as antagonist, Antagonist binding to PPARalpha ligand binding domain leads to Decreased, PPARalpha transactivation of gene expression
1024 stabilization, PPAR alpha co-repressor leads to Decreased, PPARalpha transactivation of gene expression
734 Increased, Estrogen receptor (ER) activity leads to Decreased, Progesterone from corpus luteum
732 Increase, Dopaminergic activity leads to Decreased, Prolactin
1137 Inhibition, Cyclooxygenase 1 activity leads to Decreased, Prostaglandin F2alpha concentration, plasma
681 Inhibition, Cyclooxygenase activity leads to Decreased, Prostaglandin F2alpha synthesis, ovary
820 Occurrence, Cytoplasmic vacuolization (Renal tubule) leads to Decreased, Renal ability to dilute urine
824 Occurrence, Cystic dilatation (renal tubule) leads to Decreased, Renal ability to dilute urine
828 Occurrence, Cytoplasmic vacuolization (podocyte) leads to Decreased, Renal ability to dilute urine
818 Occurrence, Cytoplasmic vacuolization (Renal tubule) leads to Decreased, Renal plasma flow
822 Occurrence, Cystic dilatation (renal tubule) leads to Decreased, Renal plasma flow
826 Occurrence, Cytoplasmic vacuolization (podocyte) leads to Decreased, Renal plasma flow
1179 premature, spawning 1 leads to Decreased, Reproductive Success
1182 Delayed, Sexual maturity leads to Decreased, Reproductive Success
1188 Decreased, gametogenesis leads to Decreased, Reproductive Success
1193 increased or inappropriate, mantel display leads to Decreased, Reproductive Success
1221 induced, parturition leads to Decreased, Reproductive Success
1222 premature, Spawning leads to Decreased, Reproductive Success
1323 Induced parturition leads to Decreased, Reproductive Success
1324 induced spawning leads to Decreased, Reproductive Success
1499 Sexual behavior, decreased leads to Decreased, Reproductive Success
1500 Locomotor activity, decreased leads to Decreased, Reproductive Success
1520 Inhibit, serotonin transporter activity leads to Decreased, serotonin transporter activity
1064 Increased, T4/T3 catabolism leads to Decreased, serum T4/T3
645 Decreased, anxiety leads to Decreased, sheltering
585 Inhibition, sodium channel leads to Decreased, Sodium conductance 1
597 Inhibition, Ether-a-go-go (ERG) voltage-gated potassium channel leads to Decreased, Sodium conductance 1
1242 Inhibition, sodium channel leads to Decreased, sodium conductance 2
819 Occurrence, Cytoplasmic vacuolization (Renal tubule) leads to Decreased, Sodium reabsorption
823 Occurrence, Cystic dilatation (renal tubule) leads to Decreased, Sodium reabsorption
827 Occurrence, Cytoplasmic vacuolization (podocyte) leads to Decreased, Sodium reabsorption
654 Increased, predation leads to Decreased, survival
1642 Reduced, Swimming performance leads to Decreased, survival
1433 Decreased, packaged serotonin leads to Decreased, synaptic release
1519 Decreased, extracellular serotonin leads to Decreased, synaptic release
999 Increase, EcR agonism leads to Decreased, synthesis and secretion of molting fluid proteases
1007 Increase, EcR agonism leads to Decreased, Synthesis of molting fluid proteases
806 Decreased, cholesterol leads to Decreased, Testosterone
729 Decreased, Androgen receptor activity leads to Decreased, Testosterone binding to androgen receptor (hypothalamus)
809 TH synthesis, Decreased leads to Decreased, Thyroxine (T4) in serum
1143 T4 in serum, Decreased leads to Decreased, Thyroxine (T4) in tissues
33 N/A, Androgen receptor, Antagonism leads to Decreased, Transcription of genes by AR
1026 Inhibition, Deiodinase 2 leads to Decreased, Triiodothyronine (T3) in serum
1037 Inhibition, Deiodinase 1 leads to Decreased, Triiodothyronine (T3) in serum
1163 Decreased, Thyroxine (T4) in tissues leads to Decreased, Triiodothyronine (T3) in tissues
1198 Inhibition, Deiodinase 1 leads to Decreased, Triiodothyronine (T3) in tissues
1199 Inhibition, Deiodinase 2 leads to Decreased, Triiodothyronine (T3) in tissues
330 Binding, VEGF-A leads to Decreased, VegfR2
333 Production, VEGF-A leads to Decreased, VegfR2
1382 Inhibition, Wnt pathway leads to Defect of Embryogenesis
905 Impaired, Proteostasis leads to Degeneration of dopaminergic neurons of the nigrostriatal pathway
906 N/A, Neuroinflammation leads to Degeneration of dopaminergic neurons of the nigrostriatal pathway
908 N/A, Mitochondrial dysfunction 1 leads to Degeneration of dopaminergic neurons of the nigrostriatal pathway
446 Down Regulation, K-Cl co-transporter 2 (KCC2) leads to Delay, Developmental GABA shift
1181 Depletion, energy reserves leads to Delayed, Sexual maturity
1173 Increased, valve movement leads to Depletion, energy reserves
1176 Increased, foot detachment leads to Depletion, energy reserves
1177 Increased, locomotion leads to Depletion, energy reserves
1218 Increase, cilia movement leads to Depletion, energy reserves
1219 increased or inappropriate, mantel display leads to Depletion, energy reserves
1228 Increased, muscular waves in foot leads to Depletion, energy reserves
168 N/A, Interferences with SH-/selen-proteins leads to Depletion, GSH
1673 Inhibition, mitochondrial DNA polymerase gamma (Pol gamma) leads to Depletion, mtDNA
714 Binding, Tubulin leads to Depolymerization, Microtubule
658 Activation, Nicotinic acetylcholine receptor leads to Desensitization, Nicotinic acetylcholine receptor
1354 Activation of TGF-β signaling leads to Differentiation of Myofibroblast
972 Activation, AhR leads to dimerization, AHR/ARNT
715 Depolymerization, Microtubule leads to Disorganization, Spindle
1760 Decrease, Calcium currents leads to Disruption, Intracellular calcium mobilization
1678 Disturbance, Lysosomal function leads to Disruption, Lysosome
1775 endocytosis leads to Disruption, Lysosome
60 Increase, Ca++ (intracellular) leads to Disruption, Mitochondrial electron transport chain
1761 Disruption, Intracellular calcium mobilization leads to Disruption, Sarcomere assembly
837 Inhibition, Phospholipase A leads to Disturbance, Lysosomal function
1677 Binding of substrate, endocytic receptor leads to Disturbance, Lysosomal function
1634 Binding, topoisomerase II leads to DSB
1496 7α-hydroxypregnenolone synthesis in the brain, decreased leads to Dopamine release in the brain, decreased
519 Inhibition, FoxA2 leads to Down Regulation, CPT1A
240 Propagation, Oxidative stress leads to Down Regulation, Gulcose-6-phosphate dehydrogenase
523 Inhibition, FoxA2 leads to Down Regulation, HMGCS2
445 BDNF, Reduced leads to Down Regulation, K-Cl co-transporter 2 (KCC2)
1674 Depletion, mtDNA leads to Dysfunction, Mitochondria
1680 Alkylation, Protein leads to Dysfunction, Mitochondria
1272 Opening of calcium channel, Calcium influx leads to Sensory Airway Irritation
1355 Activation of TGF-β signaling leads to Expression of Collagen
1626 Differentiation of fibroblasts leads to Expression of Collagen
1627 EMT leads to Expression of Collagen
1722 Increase, Inflammation leads to Expression of Collagen
1167 Irreversible inhibition of hepatic VKOR by binding of AR at tyrosine 139, Failure to cycle leads to Failure in gamma-glutamyl carboxylation of clotting factors II, VII, IX and X, Under carbo
1168 Under carboxylated clotting factors will not assemble on cell surfaces to form clot, Failur leads to Failure in vascular repair mechanisms, Unresolved blood loss (hemorrhage)
1748 Decreased, PPARalpha transactivation of gene expression leads to Fatty Acid Beta Oxidation, Decreased
316 Decreased, Transcription of genes by AR leads to Feminisation or incomplete development, Primary and accessory male sex organs
338 Alteration, Wnt pathway leads to Feminisation or incomplete development, Primary and accessory male sex organs
1592 Systemic cholesterol increased leads to Foam cell formation
1593 HDL-SAA formation leads to Foam cell formation
1590 SAA production increased leads to HDL-SAA formation
243 N/A, Parent compound is converted to the reactive metabolite and forms free radicals leadin leads to Formation, Formation of hemoglobin adducts
876 Activation, Long term AHR receptor driven direct and indirect gene expression changes leads to Formation, Hepatocellular and Bile duct tumors
997 Alterations, Cellular proliferation / hyperplasia leads to Formation, Hepatocellular and Bile duct tumors
859 Induction, Microvesicular fat leads to Formation, Liver fibrosis
860 Formation, Mallory body leads to Formation, Liver fibrosis
298 Induction, Sustained Cell Proliferation leads to Formation, Liver tumor
852 Occurrence, Cytoplasmic vacuolization (hepatocyte) leads to Formation, Mallory body
854 Occurrence, Ballooning degeneration (hepatocyte) leads to Formation, Mallory body
856 Occurrence, Cytoplasmic vacuolization (Bile duct cell) leads to Formation, Mallory body
858 Occurrence, Cytoplasmic vacuolization (kupffer cell) leads to Formation, Mallory body
340 Activation, Pre-MIE: Metabolism of AFB1 leads to Formation, Pro-mutagenic DNA Adducts
402 Metabolism of AFB1, Production of Reactive Electrophiles leads to Formation, Pro-mutagenic DNA Adducts
1731 Lipid Peroxidation leads to General Apoptosis
1732 Unfolded Prortein Response leads to General Apoptosis
1285 Oxidization of biomolecules, Lipid bilayer and cellular proteins leads to Generation of novel epitopes , Antigen presentation
1291 Oxidation leads to Generation of novel epitopes , Antigen presentation
1576 TRPA1 activation, TRPA1 Receptor leads to Generation of novel epitopes , Antigen presentation
683 Reduction, Neuronal synaptic inhibition leads to Generation, Amplified excitatory postsynaptic potential (EPSP)
1685 Oxidative Stress leads to Glutamate dyshomeostasis
1376 Down Regulation, GSS and GSTs gene leads to Glutathione homeostasis
1373 Down Regulation, GSS and GSTs gene leads to Glutathione synthesis
1641 Reduced, Swimming performance leads to Growth, reduction
1759 Decrease, Cardiac ejection fraction leads to Heart failure
1548 Reduced, mucosal defense leads to Helicobacter pylori infection
1165 Failure in gamma-glutamyl carboxylation of clotting factors II, VII, IX and X, Under carbo leads to Hemostasis, Depletion from blood of fully functional carboxylated clotting factors
1513 Oxidative Stress leads to Hepatocytotoxicity
1515 Activation of Cyp2E1 leads to Hepatocytotoxicity
1377 Perturbation of cholesterol leads to Hepatotoxicity
1378 Glutathione homeostasis leads to Hepatotoxicity
747 Hippocampal gene expression, Altered leads to Hippocampal anatomy, Altered
1388 T4 in serum, Decreased leads to Hippocampal anatomy, Altered
746 T4 in neuronal tissue, Decreased leads to Hippocampal gene expression, Altered
1387 T4 in serum, Decreased leads to Hippocampal gene expression, Altered
749 Hippocampal anatomy, Altered leads to Hippocampal Physiology, Altered
1389 T4 in serum, Decreased leads to Hippocampal Physiology, Altered
1709 Histone deacetylase inhibition leads to Histone acetylation, increase
69 Proliferation, Cell proliferation in the absence of cytotoxicity leads to Hyperplasia, Hyperplasia
398 Increase proliferation, Leydig cell leads to Hyperplasia, Leydig cell
1113 Increased, circulating estrogen levels leads to Hyperplasia, Mammary gland
1114 Increased, prolactin exposure leads to Hyperplasia, Mammary gland
1091 Increased, secrection of FSH from anterior pituitary leads to Hyperplasia, ovarian epithelium
1090 Increased, secrection of FSH from anterior pituitary leads to Hyperplasia, ovarian stromal cells
1092 Increased, secretion of LH from anterior pituitary leads to Hyperplasia, ovarian stromal cells
758 Increased, Chloride conductance leads to hyperpolarisation, neuron
1565 Opening of GIRK channels leads to hyperpolarisation, neuron
989 Goblet cell hyperplasia leads to Hypersecretion, Mucus
990 Occurrence, Metaplasia of goblet cells leads to Hypersecretion, Mucus
991 Increase, Mucin production leads to Hypersecretion, Mucus
983 Increase, Vascular Resistance leads to Hypertension
1082 Proliferation/Clonal Expansion, smooth muscle leads to Hypertrophy/hyperplasia, smooth muscle
1277 Non-neuronal production of TNF, Epithelial irritation leads to Leukocyte infiltration
1577 SP (Substance P) release, Local increase of SP leads to Leukocyte infiltration
1585 Increased NKA leads to Leukocyte infiltration
1586 Increased CGRP leads to Leukocyte infiltration
127 Agonism, Estrogen receptor leads to Impaired development of, Reproductive organs
1171 Reduced fitness or even mortality, Acidosis, hypovolemic shock and organ dysfunction leads to Impaired recruitment , Population trajectory
571 Increased, Viral susceptibility leads to impaired, Development
394 irregularities, ovarian cycle leads to impaired, Fertility
405 Malformation, Male reproductive tract leads to impaired, Fertility
462 Hyperplasia, Leydig cell leads to impaired, Fertility
1650 Decreased sperm quantity or quality in the adult, Decreased fertility leads to impaired, Fertility
573 Decrease, Number of worker bees leads to impaired, Hive thermoregulation
665 impaired, Thoracic shivering leads to impaired, Hive thermoregulation
1152 N/A, Mitochondrial dysfunction 1 leads to impaired, Hive thermoregulation
562 Reduced, Food storage leads to impaired, Larval development
566 Reduced, Brood care leads to impaired, Larval development
904 N/A, Mitochondrial dysfunction 1 leads to Impaired, Proteostasis
664 N/A, Mitochondrial dysfunction 1 leads to impaired, Thoracic shivering
36 Reduction, Angiogenesis leads to Impairment, Endothelial network
975 reduced production, VEGF leads to Impairment, Endothelial network
62 Decreased, Calcium influx leads to Impairment, Learning and memory
214 Inhibition, NMDARs leads to Impairment, Learning and memory
228 Binding of antagonist, NMDA receptors leads to Impairment, Learning and memory
359 Neuronal network function, Decreased leads to Impairment, Learning and memory
634 Decreased, Neuronal network function in adult brain leads to Impairment, Learning and memory
1069 N/A, Neurodegeneration leads to Impairment, Learning and memory
1146 Activation, Nicotinic acetylcholine receptor leads to Impairment, Learning and memory
1310 Altered, Ca2+-calmodulin activated signal transduction leads to Impairment, Learning and memory
1503 Inhibition, Na+/I- symporter (NIS) leads to Impairment, Learning and memory
1506 TH synthesis, Decreased leads to Impairment, Learning and memory
1507 BDNF, Reduced leads to Impairment, Learning and memory
1643 Decrease, histaminergic neuron excitation leads to Impairment, Learning and memory
1020 Reduction, NFAT/AP-1 complex formation leads to Impairment, T-cell dependent antibody response
1258 Suppression, Suppression of production of cytotoxic T-cells leads to Impairment, T-cell dependent antibody response
1510 Suppression, IL-2 and IL-4 production leads to Impairment, T-cell dependent antibody response
1436 Decreased, extracellular serotonin leads to Inactivated, 5-HTR
1465 Increased, intracellular chloride (Cl-) leads to Inactive, membrane depolarization
1237 Peptide Oxidation leads to Increase activation, Nuclear factor kappa B (NF-kB)
461 Increase, Luteinizing hormone (LH) leads to Increase proliferation, Leydig cell
728 Increase, Hyperplasia (terminal bronchiolar cells) leads to Increase, Adenomas/carcinomas (bronchioloalveolar)
743 Increase, Hyperplasia (follicular cells) leads to Increase, Adenomas/carcinomas (follicular cell)
764 Peptide Oxidation leads to Increase, Adenomas/carcinomas (hepatocellular)
766 Increase, Cytotoxicity leads to Increase, Adenomas/carcinomas (hepatocellular)
774 Increase, Preneoplastic foci (hepatocytes) leads to Increase, Adenomas/carcinomas (hepatocellular)
1232 Increase, Clonal Expansion / Cell Proliferatin to form Pre-Neoplastic Altered Hepatic Foci leads to Increase, Adenomas/carcinomas (hepatocellular)
761 Increase, Hyperplasia (renal tubular cells) leads to Increase, Adenomas/carcinomas (renal tubular)
786 Increase, Hyperplasia (tubular epithelial cells) leads to Increase, Adenomas/carcinomas (renal tubular)
798 Increase, Hyperplasia (urothelial) leads to Increase, Adenomas/carcinomas (urothelial)
1701 Activation/Proliferation, T-cells leads to Increase, Allergic Respiratory Hypersensitivity Response
1546 Helicobacter pylori infection leads to Increase, ammonium (NH4+)
723 Altered, Chromosome number leads to Increase, Aneuploid offspring
1479 Activation, PTGS-2 leads to Increase, angiogenesis
1468 Increase, DNA Damage leads to Increase, Apoptosis
1750 Decrease, Mitochondrial ATP production leads to Increase, Apoptosis
1483 Activation, PTGS-1 leads to Increase, bicarbonate
1206 Increased, Hepatic thyroid hormone uptake/transport leads to Increase, Biliary excretion TH glucuronide
61 Inhibition, Ca++ ATPase leads to Increase, Ca++ (intracellular)
899 Increase, Mutations leads to Increase, Cancer
901 Alkylation, DNA leads to Increase, Cancer
1745 Increase, SUR binding leads to Increase, Cell membrane depolarization
889 Increase, Respiratory or Squamous Metaplasia leads to Increase, Cell Proliferation
1250 Increased, ER binding to DNA (classical pathway) leads to Increase, Cell Proliferation (Epithelial Cells)
1251 Increased, ER binding to T.F. to DNA (non-classical pathway) leads to Increase, Cell Proliferation (Epithelial Cells)
636 Increased, serotonin (5-HT) 1 leads to Increase, cilia movement
1318 Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT) leads to Increase, cilia movement
1333 Increased, serotonin (5-HT) leads to Increase, cilia movement
1231 modulation, Genes/proteins that regulate hepatocyte fate leads to Increase, Clonal Expansion / Cell Proliferatin to form Pre-Neoplastic Altered Hepatic Foci
1239 Increase, Mitogenic cell proliferation (hepatocytes) leads to Increase, Clonal Expansion / Cell Proliferatin to form Pre-Neoplastic Altered Hepatic Foci
1350 dimerization, AHR/ARNT leads to Increase, COX-2 expression
1401 Activation, L-FABP leads to Increase, cytosolic fatty acid
1405 Increased, lipogenesis leads to Increase, cytosolic fatty acid
1692 Inhibition of fatty acid beta oxidation leads to Increase, cytosolic fatty acid
765 Peptide Oxidation leads to Increase, Cytotoxicity
886 Decrease, Intracellular pH leads to Increase, Cytotoxicity
776 Increased, Plasma tyrosine leads to Increase, Cytotoxicity (corneal cells)
707 Increased, Accumulation of alpha2u microglobulin (proximal tubular epithelium) leads to Increase, Cytotoxicity (renal tubular cell)
1675 Dysfunction, Mitochondria leads to Increase, Cytotoxicity (renal tubular cell)
1679 Disruption, Lysosome leads to Increase, Cytotoxicity (renal tubular cell)
1682 Decrease, Mitochondrial ATP production leads to Increase, Cytotoxicity (renal tubular cell)
795 Increase, Urinary bladder calculi leads to Increase, Cytotoxicity (urothelial cells)
1624 Increased, secretion of local growth factors leads to Differentiation of fibroblasts
1633 Sustained inflammatory cytokine release leads to Differentiation of fibroblasts
1652 TGFbeta pathway activation leads to Differentiation of fibroblasts
1300 Increased, Oxidative Stress leads to Increase, DNA Damage
1467 Peptide Oxidation leads to Increase, DNA Damage
1595 Increase, Excessive ROS generation leads to Increase, DNA Damage
1602 Increase, ROS production leads to Increase, DNA Damage
984 Activation, AhR leads to Increase, Early Life Stage Mortality
1567 Altered, Cardiovascular development/function leads to Increase, Early Life Stage Mortality
770 Increase, Dopaminergic activity leads to Increase, Endometrial adenocarcinomas
771 Increase, Hyperplasia (glandular epithelial cells of endometrium) leads to Increase, Endometrial adenocarcinomas
1740 PSII activity leads to Increase, Excessive ROS generation
66 Up Regulation, CD36 leads to Increase, FA Influx
1596 Increase, Apoptosis leads to Increase, Follicular atresia
1344 Increase, E75b expression leads to Increase, Ftz-f1 expression
1461 Activate, presynaptic neuron 2 leads to Increase, GABA
1233 Activation, PPARα leads to Increase, Genes involved in fatty acid oxidation
1672 Decrease, Leaf development leads to Increase, Growth inhibition
23 Alkylation, DNA leads to Increase, Heritable mutations in offspring
202 Increase, Mutations leads to Increase, Heritable mutations in offspring
742 Increase, Hypertrophy and proliferation (follicular cell) leads to Increase, Hyperplasia (follicular cells)
782 Increase, Regenerative cell proliferation (forestomach epithelial cells) leads to Increase, Hyperplasia (forestomach epithelial cells)
772 Decreased, Progesterone from corpus luteum leads to Increase, Hyperplasia (glandular epithelial cells of endometrium)
730 Decreased, Testosterone binding to androgen receptor (hypothalamus) leads to Increase, Hyperplasia (Leydig cells)
745 Increased, Luteinizing hormone (LH) leads to Increase, Hyperplasia (Leydig cells)
794 Increased, Leutinizing hormone (LH) leads to Increase, Hyperplasia (Leydig cells)
760 Increase, Regenerative cell proliferation (tubular epithelial cells) leads to Increase, Hyperplasia (renal tubular cells)
727 Increase, Regenerative cell proliferation (terminal bronchiolar epithelial cells) leads to Increase, Hyperplasia (terminal bronchiolar cells)
785 Increase, Regenerative cell proliferation (tubular epithelial cells) leads to Increase, Hyperplasia (tubular epithelial cells)
797 Increase, Regenerative cell proliferation (urothelial cells) leads to Increase, Hyperplasia (urothelial)
1444 Increase, vascular smooth muscle contraction leads to Increase, hypertension
1580 Increased CGRP leads to Increase, hypertension
741 Increase, Thyroid-stimulating hormone (TSH) leads to Increase, Hypertrophy and proliferation (follicular cell)
1000 Decrease, Circulating ETH leads to Increase, Incomplete ecdysis
1001 Decreased, synthesis and secretion of molting fluid proteases leads to Increase, Incomplete ecdysis
1010 Decrease, Abdominal muscle contraction leads to Increase, Incomplete ecdysis
1011 Decreased, Digestion of old cuticle leads to Increase, Incomplete ecdysis
1022 Reduction, NFAT/AP-1 complex formation leads to Increase, Increased susceptibility to infection
1259 Suppression, Suppression of T-cell dependent antibody production leads to Increase, Increased susceptibility to infection
1260 Suppression, Suppression of production of cytotoxic T-cells leads to Increase, Increased susceptibility to infection
108 Release, Cytokine leads to Increase, Inflammation
780 Increase, Cytotoxicity (epithelial cells) leads to Increase, Inflammation
1720 Activation of PPARγ leads to Increase, Inflammation
1721 Activation of TGF-β signaling leads to Increase, Inflammation
777 Increase, Cytotoxicity (corneal cells) leads to Increase, Inflammation (corneal cells)
1439 Activate, PLC leads to Increase, inositol triphosphate
1440 Increase, inositol triphosphate leads to Increase, intracellular calcium
731 Increase, Hyperplasia (Leydig cells) leads to Increase, Leydig cell tumors
1598 Increase, Excessive ROS generation leads to Increase, Lipid peroxidation
1603 Increase, ROS production leads to Increase, Lipid peroxidation
277 Damaging, Red blood cells; hemolysis leads to Increase, Liver and splenic hemosiderosis
460 Reduction, testosterone level leads to Increase, Luteinizing hormone (LH)
711 Activation, Constitutive androstane receptor leads to Increase, Mitogenic cell proliferation (hepatocytes)
787 Activation, Androgen receptor leads to Increase, Mitogenic cell proliferation (hepatocytes)
1230 modulation, Genes/proteins that regulate hepatocyte fate leads to Increase, Mitogenic cell proliferation (hepatocytes)
1269 Altered expression of hepatic CAR-dependent genes leads to Increase, Mitogenic cell proliferation (hepatocytes)
262 Induction, Pre-mature molting leads to Increase, Mortality
1002 Increase, Incomplete ecdysis leads to Increase, Mortality
1352 Altered, Cardiovascular development/function leads to Increase, Mortality
1744 Increase, Premature molting leads to Increase, Mortality
1751 Increase, Apoptosis leads to Increase, Mortality
986 Activation, EGFR leads to Increase, Mucin production
987 Activation, Sp1 leads to Increase, Mucin production
1312 Goblet cell hyperplasia leads to Increase, Mucin production
1313 Occurrence, Metaplasia of goblet cells leads to Increase, Mucin production
1481 Activation, PTGS-1 leads to Increase, mucosal blood flow
1482 Activation, PTGS-1 leads to Increase, mucous
25 Alkylation, DNA leads to Increase, Mutations
164 N/A, Insufficient or incorrect DNA repair leads to Increase, Mutations
893 Increase, Cell Proliferation leads to Increase, Mutations in Critical Genes
1442 Activate, calmodulin leads to Increase, myosin light chain phosphorylation
767 Increase, Cytotoxicity (club cells) leads to Increase, Necrosis (terminal bronchiolar cells)
1343 Increase, EcR agonism leads to Increase, E75b expression
1746 Increase, Cell membrane depolarization leads to Increase, Opening of voltage-dependent calcium channel
762 Increased, Induction of pyruvate dehydrogenase (PDH) leads to Increase, Oxidative metabolism
1361 ROS formation leads to Increase, Oxidative Stress / Activation, PMK-1 P38 MAPK
779 Increase, Regenerative cell proliferation (corneal cells) leads to Increase, Papillomas/carcinomas (squamous cells)
783 Increase, Hyperplasia (forestomach epithelial cells) leads to Increase, Papillomas/carcinomas (squamous cells)
977 Altered, Cardiovascular development/function leads to Increase, Pericardial edema
1240 Increase, Genes involved in fatty acid oxidation leads to Increase, Peroxisomal Fatty Acid Beta Oxidation of Fatty Acids
336 Increase, Vitellogenin synthesis in liver leads to Increase, Plasma vitellogenin concentrations
1480 Activation, PTGS-1 leads to Increase, platelet aggregation
638 Increased, locomotion leads to Increase, predation
1183 Increased, foot detachment leads to Increase, predation
1185 Depletion, energy reserves leads to Increase, predation
1227 Increased, valve movement leads to Increase, predation
1743 Decrease, Cuticular chitin synthesis leads to Increase, Premature molting
773 Increase, Mitogenic cell proliferation (hepatocytes) leads to Increase, Preneoplastic foci (hepatocytes)
789 Increase, Regenerative cell proliferation (hepatocytes) leads to Increase, Preneoplastic foci (hepatocytes)
939 Activation, Epidermal Growth Factor Receptor leads to Increase, Proliferation of goblet cells
970 Activation, EGFR leads to Increase, Proliferation of goblet cells
279 Damaging, Red blood cells; hemolysis leads to Increase, RBC congestion in liver
189 Disruption, Mitochondrial electron transport chain leads to Increase, ROS production
911 Disruption, Lysosome leads to Increase, ROS production
1631 Cell damage sensing leads to Increase, ROS production
778 Increase, Inflammation (corneal cells) leads to Increase, Regenerative cell proliferation (corneal cells)
781 Increase, Inflammation leads to Increase, Regenerative cell proliferation (forestomach epithelial cells)
788 Increase, Cytotoxicity (hepatocytes) leads to Increase, Regenerative cell proliferation (hepatocytes)
726 Increase, Necrosis (terminal bronchiolar cells) leads to Increase, Regenerative cell proliferation (terminal bronchiolar epithelial cells)
708 Increase, Cytotoxicity (renal tubular cell) leads to Increase, Regenerative cell proliferation (tubular epithelial cells)
784 Increase, Cytotoxicity (tubular epithelial cells) leads to Increase, Regenerative cell proliferation (tubular epithelial cells)
796 Increase, Cytotoxicity (urothelial cells) leads to Increase, Regenerative cell proliferation (urothelial cells)
254 Increase, Plasma vitellogenin concentrations leads to Increase, Renal pathology due to VTG deposition
888 Increase, Tissue Degeneration, Necrosis & Atrophy leads to Increase, Respiratory or Squamous Metaplasia
1459 Increased, hippocampal hyperdepolarization leads to Increase, seizure
891 Increased, Induced Mutations in Critical Genes leads to Increase, Site of Contact Nasal Tumors
894 Increase, Mutations in Critical Genes leads to Increase, Site of Contact Nasal Tumors
895 Increase, Cell Proliferation leads to Increase, Site of Contact Nasal Tumors
769 Decrease, Serum thyroid hormone (T4/T3) leads to Increase, Thyroid-stimulating hormone (TSH)
887 Increase, Cytotoxicity leads to Increase, Tissue Degeneration, Necrosis & Atrophy
1599 Increase, Lipid peroxidation leads to Increase, Uncoupling of OXPHOS
1754 Increase, ROS production leads to Increase, Uncoupling of OXPHOS
1443 Increase, myosin light chain phosphorylation leads to Increase, vascular smooth muscle contraction
128 Agonism, Estrogen receptor leads to Increase, Vitellogenin synthesis in liver
1079 Activation, beta-2 adrenergic receptor leads to Increased activity, beta-2 adrenergic receptor
1609 Activation of specific nuclear receptors, PPAR-gamma activation leads to increased adipogenesis
1611 activation of CEBPA leads to increased adipogenesis
1068 Increased, Hyperplasia (follicular cells) leads to Increased Apoptosis, Adenomas/carcinomas (follicular cell)
1645 GR Agonist, Activation leads to Increased apoptosis, decreased Leydig Cells
1578 Excitation, Trigeminal nerve excitation leads to Increased CGRP
1319 Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT) leads to increased mantel display
1336 Increased, serotonin (5-HT) leads to increased mantel display
1583 Excitation, Trigeminal nerve excitation leads to Increased NKA
1192 Increased, serotonin (5-HT) 1 leads to increased or inappropriate, mantel display
1763 Tissue resident cell activation leads to Increased pro-inflammatory mediators
1776 N/A, Cell injury/death leads to Increased pro-inflammatory mediators
1589 Pro-inflammatory cytokines increased leads to SAA production increased
1588 Sensing of the stressor leads to Pro-inflammatory cytokines increased
1278 Leukocyte infiltration leads to Respiratory irritability
1581 Increase, hypertension leads to Respiratory irritability
1587 Increased CGRP leads to Respiratory irritability
1771 Increased Airway Hyper-responsiveness,Cough, Dyspnea leads to Respiratory irritability
1772 SP (Substance P) release, Local increase of SP leads to Respiratory irritability
1773 Increased NKA leads to Respiratory irritability
1591 HDL-SAA formation leads to Systemic cholesterol increased
1435 Decreased, extracellular serotonin leads to Increased, 5-HT3
706 Increased, Binding of chemicals to 2u (serum) leads to Increased, Accumulation of alpha2u microglobulin (proximal tubular epithelium)
67 N/A, Cell injury/death leads to Increased, Activation and Recruitment of Hepatic macrophages (Kupffer Cells)
236 Peptide Oxidation leads to Increased, Activation and Recruitment of Hepatic macrophages (Kupffer Cells)
1705 Loss of alveolar capillary membrane integrity leads to Activation of Th2 cells
1120 Increased, lactotroph hyperplasia and hypertrophy leads to Increased, adenomas (pituitary)
1116 Hyperplasia, Mammary gland leads to Increased, Adenomas/carcinomas (mammary)
1117 Increased, latency period leads to Increased, Adenomas/carcinomas (mammary)
1124 Increased, hyperplasia (mammary gland) leads to Increased, Adenomas/carcinomas (mammary)
1107 Increased, Hyperplasia (glandular epithelial cells of endometrium) leads to Increased, adenosquamous carcinomas of endometrium
1071 Activation of specific nuclear receptors, PPAR-gamma activation leads to Increased, adipogenesis
1448 Decreased, neuroplasticity leads to Increased, agitation
593 N/A, hypoxia leads to Increased, amputations
1266 Increased, Proliferation (Endothelial cells) leads to Increased, Angiogenesis
1267 Increased, Migration (Endothelial Cells) leads to Increased, Angiogenesis
567 Increase, Energetic demands and therefore metabolic stress leads to Increased, Appetite and hunger
606 Overactivation, muscle contraction leads to Increased, Ataxia, paralysis, or hyperactivity
449 Inhibition, Acetylcholinesterase (AchE) leads to Increased, Atrioventricular block and bradycardia
454 Accumulation, Acetylcholine in synapses leads to Increased, Atrioventricular block and bradycardia
590 Inhibition, sodium channel leads to Increased, Atrioventricular block and bradycardia
594 Decreased, Sodium conductance 1 leads to Increased, Atrioventricular block and bradycardia
1134 Occurrence, renal proximal tubular necrosis leads to Increased, blood potassium concentration
1131 Inhibition, organic anion transporter 1 (OAT1) leads to Increased, blood uric acid concentration
1156 Occurrence, renal proximal tubular necrosis leads to Increased, blood uric acid concentration
702 Altered, Action Potential leads to Increased, cardiac arrthymia
884 Not Increased, Circulating Ketone Bodies leads to Increased, Catabolism of Muscle Protein
1129 Increased, secretion of local growth factors leads to Increased, Cell Proliferation (mesothelium)
1098 prolonged, elevation of serun CCK leads to Increased, Cellular proliferation / hyperplasia of acinar cells
752 Activation, Glutamate-gated chloride channel leads to Increased, Chloride conductance
1051 Activation, ionotropic GABA Receptor chloride channel leads to Increased, Chloride conductance
1057 Activation, Glutamate-gated chloride channels leads to Increased, Chloride conductance
1096 Increased, PPAR-alpha activation leads to Increased, cholestasis
1101 Decreased, bile flow leads to Increased, cholestasis
699 Upregulated, Spindle assembly checkpoint protein Mad2-oocyte leads to Increased, Chromosome misseggregation
1208 Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT) leads to Increased, cilia movement
1209 Increased, serotonin (5-HT) leads to Increased, cilia movement
1111 prolonged, estrus leads to Increased, circulating estrogen levels
1118 interruption, Ovulation leads to Increased, circulating estrogen levels
351 Increased, Induced Mutations in Critical Genes leads to Increased, Clonal Expansion / Cell Proliferatin to form Pre-Neoplastic Altered Hepatic Foci
352 Formation, Pro-mutagenic DNA Adducts leads to Increased, Clonal Expansion / Cell Proliferatin to form Pre-Neoplastic Altered Hepatic Foci
694 Reduced, Maturation inducing steroid receptor signalling, oocyte leads to Increased, cyclic adenosine monophosphate
482 Activation, SREBF1 leads to Increased, De Novo FA synthesis
483 Activation, ChREBP leads to Increased, De Novo FA synthesis
492 Up Regulation, FAS leads to Increased, De Novo FA synthesis
517 Up Regulation, Acetyl-CoA carboxylase-1 (ACC-1) leads to Increased, De Novo FA synthesis
1606 Activation, LXR alpha leads to Increased, De Novo FA synthesis
1449 Decreased, neuroplasticity leads to Increased, depression
1025 Abnormal, Morphogenesis leads to Increased, Developmental Defects
1036 Insufficiency, Vascular leads to Increased, Developmental Defects
389 Decreased, Lymphocytes leads to Increased, Disease susceptibility
1362 Increase, Oxidative Stress / Activation, PMK-1 P38 MAPK leads to Increased, DNA Damage-Repair
1247 Increase, Cell Proliferation (Epithelial Cells) leads to Increased, Ductal Hyperplasia
1248 Decreased, Apoptosis (Epithelial Cells) leads to Increased, Ductal Hyperplasia
1460 Increase, seizure leads to Increased, epilepsy
1550 Increased, seizure leads to Increased, epilepsy
1246 Activation, Estrogen receptor leads to Increased, ER binding to DNA (classical pathway)
1249 Activation, Estrogen receptor leads to Increased, ER binding to T.F. to DNA (non-classical pathway)
1295 Increased, Non-genomic signaling leads to Increased, ER binding to T.F. to DNA (non-classical pathway)
733 Decreased, Prolactin leads to Increased, Estrogen receptor (ER) activity
1707 Increased cellular proliferation and differentiation leads to Increased extracellular matrix deposition
1430 Decreased, serotonin transporter activity leads to Increased, extracellular serotonin
1527 Increased, synaptic release leads to Increased, extracellular serotonin
496 Activation, AhR leads to Increased, FA Influx
501 Up Regulation, CD36 leads to Increased, FA Influx
1659 demethylation, PPARg promoter leads to Increased, FA Influx
1706 Activation of Th2 cells leads to Increased cellular proliferation and differentiation
1076 Increased, proliferation of mesenchymal cells leads to Increased, Firbrosarcoma
639 Increase, cilia movement leads to Increased, foot detachment
642 Increased, muscular waves in foot leads to Increased, foot detachment
1175 Increased, water retention in foot leads to Increased, foot detachment
1452 Activated, presynaptic neuron 1 leads to Increased, glutamate
1078 Increased, proliferation of mesenchymal cells leads to Increased, hemagiosarcoma
1204 Activation, Hepatic nuclear receptor(s) leads to Increased, Hepatic thyroid hormone uptake/transport
802 modulation, Unknown leads to Increased, HIF-1 alpha transcription
799 Inhibition, Prolyl hydroxylases leads to Increased, HIF-1 heterodimer
803 Increased, HIF-1 alpha transcription leads to Increased, HIF-1 heterodimer
1458 Activated, membrane depolarization leads to Increased, hippocampal hyperdepolarization
1067 Increased, Hypertrophy and proliferation (follicular cell) leads to Increased, Hyperplasia (follicular cells)
1106 squamous metaplasia, aberrant basal cells leads to Increased, Hyperplasia (glandular epithelial cells of endometrium)
1122 Increased, prolactin secretion leads to Increased, hyperplasia (mammary gland)
1066 Increased, Thyroid-stimulating hormone (TSH) leads to Increased, Hypertrophy and proliferation (follicular cell)
1075 Increased, secretion of local growth factors leads to Increased, IGF-1 (mouse)
547 Increased, Insufficient repair or mis-repair of pro-mutagenic DNA adducts leads to Increased, Induced Mutations in Critical Genes
890 Increase, Cell Proliferation leads to Increased, Induced Mutations in Critical Genes
716 Inhibition, Pyruvate dehydrogenase kinase (PDK) enzyme leads to Increased, Induction of pyruvate dehydrogenase (PDH)
1125 persistent, cytotoxicity (pleura or peritoneum) leads to Increased, inflammation
1047 Increased, Chloride influx leads to Increased, Inhibitory postsynaptic potential
1053 Increased, Neuronal synaptic inhibition leads to Increased, Inhibitory postsynaptic potential
548 Formation, Pro-mutagenic DNA Adducts leads to Increased, Insufficient repair or mis-repair of pro-mutagenic DNA adducts
361 Overactivation, NMDARs leads to Increased, Intracellular Calcium overload
1427 Decreased, serotonin transporter activity leads to Increased, intracellular chloride (Cl-)
1464 Activate, GABA-A receptor leads to Increased, intracellular chloride (Cl-)
1524 Increased, serotonin transporter activity leads to Increased, intracellular serotonin
1426 Decreased, serotonin transporter activity leads to Increased, intracellular sodium (Na+)
1454 Activated, NMDA receptor leads to Increased, intracellular sodium (Na+)
1306 Increased, Motility leads to Increased, Invasion
751 N/A, Unknown leads to Increased, Kidney Failure
1119 Increased, circulating estrogen levels leads to Increased, lactotroph hyperplasia and hypertrophy
1115 Hyperplasia, Mammary gland leads to Increased, latency period
1123 Increased, hyperplasia (mammary gland) leads to Increased, latency period
507 Up Regulation, LDLR (low density lipoprotein receptor) leads to Increased, LDL uptake
196 Abnormal, Morphogenesis leads to Increased, Lethality
296 Increased, Structural malformations leads to Increased, Lethality
1544 Increased, leukocyte adherence leads to Increased, leukocyte activation
1543 Reduced, PTGS2 function leads to Increased, leukocyte adherence
793 Decrease, Bioactivation of testosterone leads to Increased, Leutinizing hormone (LH)
1404 Activation, SCD-1 leads to Increased, lipogenesis
1422 Activation, FAS leads to Increased, lipogenesis
1077 Increased, proliferation of mesenchymal cells leads to Increased, liposarcoma
486 Increased, Triglyceride formation leads to Increased, Liver Steatosis
515 Accumulation, Fatty acid leads to Increased, Liver Steatosis
538 Inhibition, Mitochondrial fatty acid beta-oxidation leads to Increased, Liver Steatosis
617 Decreased, Mitochondrial fatty acid beta-oxidation leads to Increased, Liver Steatosis
1607 Increased, De Novo FA synthesis leads to Increased, Liver Steatosis
1662 Activation, SREBF1 leads to Increased, Liver Steatosis
1694 Increase, cytosolic fatty acid leads to Increased, Liver Steatosis
637 Increase, cilia movement leads to Increased, locomotion
641 Increased, muscular waves in foot leads to Increased, locomotion
1189 Increased, serotonin (5-HT) 1 leads to Increased, locomotion
1704 Recruitment of inflammatory cells leads to Loss of alveolar capillary membrane integrity
744 Decreased, Testosterone binding to androgen receptor (hypothalamus) leads to Increased, Luteinizing hormone (LH)
1263 Induction, Male reproductive tract leads to Increased, Male offspring
1207 Increased, serotonin (5-HT) leads to Increased, mantel display
1130 Increased, Cell Proliferation (mesothelium) leads to Increased, mesotheliomas
263 Induction, Pre-mature molting leads to Increased, Mortality
432 Increased, Atrioventricular block and bradycardia leads to Increased, Mortality
433 Increased, Respiratory distress/arrest leads to Increased, Mortality
434 Induction, Ataxia, paralysis, or hyperactivity leads to Increased, Mortality
452 Inhibition, Acetylcholinesterase (AchE) leads to Increased, Mortality
607 Increased, Ataxia, paralysis, or hyperactivity leads to Increased, Mortality
703 Increased, cardiac arrthymia leads to Increased, Mortality
757 N/A, Ataxia, paralysis, or hyperactivity leads to Increased, Mortality
1050 Induction, Somatic muscle paralysis leads to Increased, Mortality
1056 Inhibition, Feeding leads to Increased, Mortality
1136 Occurrence, cardiac arrthymia leads to Increased, Mortality
1141 Occurrence, cardiac arrhythmia leads to Increased, Mortality
1190 Increase, Incomplete ecdysis leads to Increased, Mortality
1491 Decreased, Population trajectory leads to Increased, Mortality
1305 Altered, Protein Production leads to Increased, Motility
640 Increased, serotonin (5-HT) 1 leads to Increased, muscular waves in foot
1316 Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT) leads to Increased, muscular waves in foot
1332 Increased, serotonin (5-HT) leads to Increased, muscular waves in foot
1052 Increased, Chloride conductance leads to Increased, Neuronal synaptic inhibition
1294 Activation, Estrogen receptor leads to Increased, Non-genomic signaling
1308 Increased, Second Messenger Production leads to Increased, Non-genomic signaling
1696 Increased, Reactive oxygen species leads to increased, oncotic necrosis
1212 Increased, serotonin (5-HT) leads to Increased, oocyte maturation
1337 Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT) leads to Increased, oocyte maturation
283 Increase, ROS production leads to Increased, Oxidative damage
1126 persistent, cytotoxicity (pleura or peritoneum) leads to Increased, Oxidative Stress
1158 Increased, blood uric acid concentration leads to Increased, Oxidative Stress
1159 Occurrence, renal ischemia leads to Increased, Oxidative Stress
1162 Increased, Reactive oxygen species leads to Increased, Oxidative Stress
1299 Altered, Protein Production leads to Increased, Oxidative Stress
1525 Increased, intracellular serotonin leads to Increased, packaged serotonin
1099 Increased, Cellular proliferation / hyperplasia of acinar cells leads to Increased, Pancreatic acinar tumors
775 Inhibition, 4-hydroxyphenyl-pyruvate dioxygenase (HPPD) enzyme leads to Increased, Plasma tyrosine
1211 premature, Spawning leads to Increased, Population
1215 Increased, Reproductive Success leads to Increased, Population
588 Reduced, swimming speed leads to Increased, predation
589 Reduced, feeding 1 leads to Increased, predation
646 Decreased, sheltering leads to Increased, predation
651 Decreased, locomotion leads to Increased, predation
1112 prolonged, estrus leads to Increased, prolactin exposure
1121 Decreased, Dopaminergic activity leads to Increased, prolactin secretion
1303 Altered, Protein Production leads to Increased, Proliferation (Endothelial cells)
1074 Increased, secretion of local growth factors leads to Increased, proliferation of mesenchymal cells
342 Increased, Induced Mutations in Critical Genes leads to Increased, Proliferation/Clonal Expansion of Mutant Cells (Pre-Neoplastic Lesions/Altered H
344 Formation, Pro-mutagenic DNA Adducts leads to Increased, Proliferation/Clonal Expansion of Mutant Cells (Pre-Neoplastic Lesions/Altered H
1161 Unknown, MIE leads to Increased, Reactive oxygen species
1695 Increased, Liver Steatosis leads to Increased, Reactive oxygen species
1703 Increased proinflammatory mediators leads to Recruitment of inflammatory cells
1213 Increased, oocyte maturation leads to Increased, Reproductive Success
1214 Increased, mantel display leads to Increased, Reproductive Success
1325 induced spawning leads to Increased, Reproductive Success
1326 Induced parturition leads to Increased, Reproductive Success
450 Inhibition, Acetylcholinesterase (AchE) leads to Increased, Respiratory distress/arrest
457 Induction, Ataxia, paralysis, or hyperactivity leads to Increased, Respiratory distress/arrest
591 Increased, Atrioventricular block and bradycardia leads to Increased, Respiratory distress/arrest
1307 Activation, Estrogen receptor leads to Increased, Second Messenger Production
1088 Increased, secretion of GnRH from hypothalamus leads to Increased, secrection of FSH from anterior pituitary
1084 Decreased, Ovarian E2 leads to Increased, secretion of GnRH from hypothalamus
1087 Decrease, E2 blood concentrations at hypothalamus leads to Increased, secretion of GnRH from hypothalamus
1089 Increased, secretion of GnRH from hypothalamus leads to Increased, secretion of LH from anterior pituitary
1072 Activation of specific nuclear receptors, PPAR-gamma activation leads to Increased, secretion of local growth factors
1073 Increased, adipogenesis leads to Increased, secretion of local growth factors
1127 Increased, inflammation leads to Increased, secretion of local growth factors
1128 Increased, Oxidative Stress leads to Increased, secretion of local growth factors
1622 Sustained inflammatory cytokine release leads to Increased, secretion of local growth factors
1623 Increase, ROS production leads to Increased, secretion of local growth factors
1632 Cell damage sensing leads to Increased, secretion of local growth factors
1702 Interaction with the cell membrane leads to Increased proinflammatory mediators
1445 Increased, 5-HT3 leads to Increased, seizure
1530 Decreased, 5-HT3 leads to Increased, seizure
1549 Increased, hippocampal hyperdepolarization leads to Increased, seizure
643 Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT) leads to Increased, serotonin (5-HT)
635 Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT) leads to Increased, serotonin (5-HT) 1
810 TH synthesis, Decreased leads to Increased, Serum creatinine
1562 Reduced, fatty acid beta oxidation leads to Increased, steatosis
197 Abnormal, Morphogenesis leads to Increased, Structural malformations
1526 Increased, packaged serotonin leads to Increased, synaptic release
1063 Increased, induction of UDPGT's in liver leads to Increased, T4/T3 catabolism
1065 Decreased, serum T4/T3 leads to Increased, Thyroid-stimulating hormone (TSH)
484 Increased, De Novo FA synthesis leads to Increased, Triglyceride formation
493 Up Regulation, SCD-1 leads to Increased, Triglyceride formation
514 Accumulation, Fatty acid leads to Increased, Triglyceride formation
1658 Increased, FA Influx leads to Increased, Triglyceride formation
1200 Inhibition, Deiodinase 3 leads to Increased, Triiodothyronine (T3) in tissues
1172 Increased, serotonin (5-HT) 1 leads to Increased, valve movement
1223 Increased, water retention in foot leads to Increased, valve movement
1317 Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT) leads to Increased, valve movement
1327 Increased, serotonin (5-HT) leads to Increased, valve movement
570 Suppression, Immune system leads to Increased, Viral susceptibility
1216 Increased, valve movement leads to Increased, water pumping
1217 Increase, cilia movement leads to Increased, water pumping
1174 Increased, valve movement leads to Increased, water retention in foot
1224 Increased, water pumping leads to Increased, water retention in foot
1630 Cell damage sensing leads to Sustained inflammatory cytokine release
1322 increased mantel display leads to Induced parturition
1334 Increased, valve movement leads to Induced parturition
1335 Increase, cilia movement leads to Induced parturition
1320 Increased, valve movement leads to induced spawning
1321 Increase, cilia movement leads to induced spawning
1328 Increased, oocyte maturation leads to induced spawning
1329 Increased, cilia movement leads to induced spawning
1220 increased or inappropriate, mantel display leads to induced, parturition
1226 Increased, water pumping leads to induced, parturition
451 Inhibition, Acetylcholinesterase (AchE) leads to Induction, Ataxia, paralysis, or hyperactivity
456 Accumulation, Acetylcholine in synapses leads to Induction, Ataxia, paralysis, or hyperactivity
116 Increase, EcR agonism leads to Induction, Chitin degradation and resorption
869 Activation, AhR leads to Induction, CYP1A2/CYP1A5
1261 Activation, Juvenile hormone receptor leads to Induction, Doublesex1 gene
1625 Increased, secretion of local growth factors leads to EMT
1653 TGFbeta pathway activation leads to EMT
1723 Activation of TGF-β signaling leads to EMT
1724 Increase, Inflammation leads to EMT
1415 Activation, HSD17B4 leads to Induction, fatty acid beta-oxidation
385 Activation, Glucocorticoid Receptor leads to Induction, IKB inhibitory protein
93 Production, Critical Metabolites (CGA 330050 and CGA 265307) leads to Induction, Liver “Dysfunctional” Changes by CGA 330050
1262 Induction, Doublesex1 gene leads to Induction, Male reproductive tract
851 Occurrence, Cytoplasmic vacuolization (hepatocyte) leads to Induction, Microvesicular fat
853 Occurrence, Ballooning degeneration (hepatocyte) leads to Induction, Microvesicular fat
855 Occurrence, Cytoplasmic vacuolization (Bile duct cell) leads to Induction, Microvesicular fat
857 Occurrence, Cytoplasmic vacuolization (kupffer cell) leads to Induction, Microvesicular fat
1058 Increased, Inhibitory postsynaptic potential leads to Induction, pharyngeal muscle paralysis
70 Induction, Chitin degradation and resorption leads to Induction, Pre-mature molting
1049 Inhibition, Motor neuron activity leads to Induction, Somatic muscle paralysis
1054 Increased, Inhibitory postsynaptic potential leads to Induction, Somatic muscle paralysis
299 Induction, Sustained Hepatotoxicity leads to Induction, Sustained Cell Proliferation
159 Inhibition, Inducible Nitric Oxide Synthase by Metabolite CGA 265307 leads to Induction, Sustained Hepatotoxicity
1205 Activation, Hepatic nuclear receptor(s) leads to Induction, Upregulation of glucuronyltransferase activity
1331 MLL translocation leads to IFL
994 Release, Cytokine leads to Infiltration, Inflammatory cells
925 Release, Cytokine leads to Infiltration, Inflammatory cytokines
916 Infiltration, Inflammatory cells leads to Inflammation, Liver
926 Infiltration, Inflammatory cytokines leads to Inflammation, Liver
1473 Increase, angiogenesis leads to Inhibit, gastric ulcer formation
1474 Increase, platelet aggregation leads to Inhibit, gastric ulcer formation
1475 Activate, mucosal defense leads to Inhibit, gastric ulcer formation
1456 Treat, carbamazepine leads to Inhibit, voltage-gated sodium channel
1636 Thiol protein adducts leads to Inhibition of lysyl oxidase
1568 Release of G Proteins leads to Inhibition of Ca Channels
1569 Inhibition of Ca Channels leads to Inhibition of neurotransmitter release
459 Accumulation, Acetylcholine in synapses leads to Inhibition, Acetylcholinesterase (AchE)
1062 Formation, The binding of FK506 with FKBP12 leads to Inhibition, Calcineurin Activity
1253 Binding, Immunophilins leads to Inhibition, Calcineurin Activity
1055 Induction, Somatic muscle paralysis leads to Inhibition, Feeding
1059 Induction, pharyngeal muscle paralysis leads to Inhibition, Feeding
518 Activation, PXR/SXR leads to Inhibition, FoxA2
170 Induction, Liver “Dysfunctional” Changes by CGA 330050 leads to Inhibition, Inducible Nitric Oxide Synthase by Metabolite CGA 265307
1414 Activation, SHP leads to Inhibition, LRH-1
1412 Activation, SHP leads to Inhibition, LXR
473 Activation, AhR leads to Inhibition, Mitochondrial fatty acid beta-oxidation
511 Inhibition, PPAR alpha leads to Inhibition, Mitochondrial fatty acid beta-oxidation
537 Decreased, DHB4/HSD17B4 leads to Inhibition, Mitochondrial fatty acid beta-oxidation
1411 Activation, HSD17B4 leads to Inhibition, Mitochondrial fatty acid beta-oxidation
1048 Increased, Inhibitory postsynaptic potential leads to Inhibition, Motor neuron activity
933 Binding of inhibitor, NADH-ubiquinone oxidoreductase (complex I) leads to Inhibition, NADH-ubiquinone oxidoreductase (complex I)
229 Binding of antagonist, NMDA receptors leads to Inhibition, NMDARs
386 Induction, IKB inhibitory protein leads to Inhibition, Nuclear factor kappa B (NF-kB)
510 Activation, LXR leads to Inhibition, PPAR alpha
1413 Inhibition, LXR leads to Inhibition, PPAR alpha
896 Activation, SHP leads to Inhibition, SREBP1c
1416 Induction, fatty acid beta-oxidation leads to Inhibition, Steatosis
865 Oxidation, Uroporphyrinogen leads to Inhibition, UROD
331 Binding, VEGF-A leads to Inhibition, VegfR2
334 Decreased, VegfR2 leads to Inhibition, VegfR2
1381 Activation, FOXO leads to Inhibition, Wnt pathway
838 Inhibition, Phospholipase A leads to Injury, Mitochondria
125 Impairment, Endothelial network leads to Insufficiency, Vascular
1016 Activation, Suppression of NFAT activation and hindrance of nuclear localization leads to Interference, nuclear localization of NFAT
1255 Suppression, IL-2 and IL-4 production leads to Interference, nuclear localization of NFAT
1508 Inhibition, Calcineurin Activity leads to Interference, nuclear localization of NFAT
1109 Decreased, LH Surge from anterior pituitary leads to interruption, Ovulation
392 Reduction, Plasma 17beta-estradiol concentrations leads to irregularities, ovarian cycle
1582 Excitation, Trigeminal nerve excitation leads to Irritation induced sneezing
954 Oxidation, Glutathione leads to S-Glutathionylation, eNOS
1698 Peptide Oxidation leads to S-Glutathionylation, eNOS
980 Peptide Oxidation leads to Decrease, GTPCH-1
952 Decrease, GTPCH-1 leads to Decrease, Tetrahydrobiopterin
953 Decrease, Tetrahydrobiopterin leads to Uncoupling, eNOS
955 S-Glutathionylation, eNOS leads to Uncoupling, eNOS
992 Peptide Oxidation leads to Decrease, AKT/eNOS activity
956 Uncoupling, eNOS leads to Depletion, Nitric Oxide
988 Decrease, AKT/eNOS activity leads to Depletion, Nitric Oxide
958 Depletion, Nitric Oxide leads to Impaired, Vasodilation
982 Impaired, Vasodilation leads to Increase, Vascular Resistance
1777 Increased pro-inflammatory mediators leads to Leukocyte recruitment/activation
1727 Oxidative Stress in Brain leads to Lipid Peroxidation
1516 Oxidative Stress leads to Liver Cancer
1517 Hepatocytotoxicity leads to Liver Cancer
1518 Regenerative Proliferation leads to Liver Cancer
1494 CYP7B activity, inhibition leads to Locomotor activity, decreased
1495 7α-hydroxypregnenolone synthesis in the brain, decreased leads to Locomotor activity, decreased
1497 Dopamine release in the brain, decreased leads to Locomotor activity, decreased
1358 Production of α-smooth muscle actin leads to Lung fibrosis
1359 Collagen Deposition leads to Lung fibrosis
1725 EMT leads to Lung fibrosis
608 Reduction, testosterone level leads to Malformation, Male reproductive tract
807 Decreased, Testosterone leads to malformed, Male reproductive tract
1338 Decompartmentalization leads to Mitochondrial impairment
1339 Direct mitochondrial inhibition leads to Mitochondrial impairment
1340 narcosis leads to Mitochondrial impairment
1229 Activation, PPARα leads to modulation, Genes/proteins that regulate hepatocyte fate
1238 Increase activation, Nuclear factor kappa B (NF-kB) leads to modulation, Genes/proteins that regulate hepatocyte fate
301 Activation/Proliferation, T-cells leads to N/A, Allergic contact dermatitis on challenge
755 hyperpolarisation, neuron leads to N/A, Ataxia, paralysis, or hyperactivity
1252 Increased, Ductal Hyperplasia leads to N/A, Breast Cancer
269 Alkylation, Protein leads to N/A, Cell injury/death
353 BDNF, Reduced leads to N/A, Cell injury/death
363 N/A, Mitochondrial dysfunction 1 leads to N/A, Cell injury/death
1686 Glutamate dyshomeostasis leads to N/A, Cell injury/death
1687 N/A, Neuroinflammation leads to N/A, Cell injury/death
1690 Oxidative Stress leads to N/A, Cell injury/death
1719 Increased pro-inflammatory mediators leads to N/A, Cell injury/death
182 N/A, Methemoglobinemia, decreased hemoglobin, hematocrit, red blood cell number leads to N/A, Cyanosis occurs
268 Reduction, Prostaglandin E2 concentration leads to N/A, Gap
172 Activation, Long term AHR receptor driven direct and indirect gene expression changes leads to N/A, Hepatotoxicity, Hepatopathy, including a constellation of observable effects
995 Changes/Inhibition, Cellular Homeostasis and Apoptosis leads to N/A, Hepatotoxicity, Hepatopathy, including a constellation of observable effects
592 Increased, Respiratory distress/arrest leads to N/A, hypoxia
266 Feminisation or incomplete development, Primary and accessory male sex organs leads to N/A, Impairment of reproductive capacity
24 Alkylation, DNA leads to N/A, Insufficient or incorrect DNA repair
287 Binding, SH-/selen-proteins leads to N/A, Interferences with SH-/selen-proteins
82 Accumulation, Collagen leads to N/A, Liver fibrosis
169 Increase, Liver and splenic hemosiderosis leads to N/A, Methemoglobinemia, decreased hemoglobin, hematocrit, red blood cell number
272 Increase, RBC congestion in liver leads to N/A, Methemoglobinemia, decreased hemoglobin, hematocrit, red blood cell number
278 Damaging, Red blood cells; hemolysis leads to N/A, Methemoglobinemia, decreased hemoglobin, hematocrit, red blood cell number
362 Increased, Intracellular Calcium overload leads to N/A, Mitochondrial dysfunction 1
581 Activation, Nicotinic acetylcholine receptor leads to N/A, Mitochondrial dysfunction 1
912 Increase, ROS production leads to N/A, Mitochondrial dysfunction 1
922 Peptide Oxidation leads to N/A, Mitochondrial dysfunction 1
934 Inhibition, NADH-ubiquinone oxidoreductase (complex I) leads to N/A, Mitochondrial dysfunction 1
993 Disruption, Lysosome leads to N/A, Mitochondrial dysfunction 1
1683 Binding, SH/SeH proteins involved in protection against oxidative stress leads to N/A, Mitochondrial dysfunction 1
208 N/A, Neuroinflammation leads to N/A, Neurodegeneration
364 N/A, Cell injury/death leads to N/A, Neurodegeneration
207 N/A, Neurodegeneration leads to N/A, Neuroinflammation
210 N/A, Neuronal dysfunction leads to N/A, Neuroinflammation
365 N/A, Cell injury/death leads to N/A, Neuroinflammation
656 Synaptogenesis, Decreased leads to N/A, Neuroinflammation
907 Degeneration of dopaminergic neurons of the nigrostriatal pathway leads to N/A, Neuroinflammation
215 Inhibition, NMDARs leads to N/A, Neuronal dysfunction
239 N/A, Oxidative stress leads to N/A, Neuronal dysfunction
144 Depletion, GSH leads to N/A, Oxidative stress
123 Reduction, Eggshell thickness leads to N/A, Reproductive failure
649 Decrease, histaminergic neuron excitation leads to N/A, sedation
1693 Increase, cytosolic fatty acid leads to steatohepatitis
1697 increased, oncotic necrosis leads to steatohepatitis
750 Activation, 5HT2c leads to N/A, Unknown
1342 Mitochondrial impairment leads to Necrosis
1733 General Apoptosis leads to Neurodegeneration
1284 TRPA1 activation, TRPA1 Receptor leads to Non-neuronal production of IL-8/CXCL1, Epithelial irritation
1279 SP (Substance P) release, Local increase of SP leads to Non-neuronal production of TNF, Epithelial irritation
883 Decreased, Ketogenesis (production of ketone bodies) leads to Not Increased, Circulating Ketone Bodies
1639 Weak collagen matrix leads to Notochord malformation
1612 increased adipogenesis leads to obesity
1618 decreased DNA methylation of tyrosine hydroxylase leads to obesity
1619 decreased methylation of dopamine transporter promoter leads to obesity
684 Generation, Amplified excitatory postsynaptic potential (EPSP) leads to Occurrence, A paroxysmal depolarizing shift
840 Damage, Lipid bilayer leads to Occurrence, Ballooning degeneration (hepatocyte)
844 Disturbance, Lysosomal function leads to Occurrence, Ballooning degeneration (hepatocyte)
848 Injury, Mitochondria leads to Occurrence, Ballooning degeneration (hepatocyte)
1140 Increased, blood potassium concentration leads to Occurrence, cardiac arrhythmia
1135 Increased, blood potassium concentration leads to Occurrence, cardiac arrthymia
812 Decreased, Thyroxine (T4) in serum leads to Occurrence, Cystic dilatation (renal tubule)
814 Increased, Serum creatinine leads to Occurrence, Cystic dilatation (renal tubule)
841 Damage, Lipid bilayer leads to Occurrence, Cytoplasmic vacuolization (Bile duct cell)
845 Disturbance, Lysosomal function leads to Occurrence, Cytoplasmic vacuolization (Bile duct cell)
849 Injury, Mitochondria leads to Occurrence, Cytoplasmic vacuolization (Bile duct cell)
839 Damage, Lipid bilayer leads to Occurrence, Cytoplasmic vacuolization (hepatocyte)
843 Disturbance, Lysosomal function leads to Occurrence, Cytoplasmic vacuolization (hepatocyte)
847 Injury, Mitochondria leads to Occurrence, Cytoplasmic vacuolization (hepatocyte)
842 Damage, Lipid bilayer leads to Occurrence, Cytoplasmic vacuolization (kupffer cell)
846 Disturbance, Lysosomal function leads to Occurrence, Cytoplasmic vacuolization (kupffer cell)
850 Injury, Mitochondria leads to Occurrence, Cytoplasmic vacuolization (kupffer cell)
815 Decreased, Thyroxine (T4) in serum leads to Occurrence, Cytoplasmic vacuolization (podocyte)
816 Increased, Serum creatinine leads to Occurrence, Cytoplasmic vacuolization (podocyte)
811 Decreased, Thyroxine (T4) in serum leads to Occurrence, Cytoplasmic vacuolization (Renal tubule)
813 Increased, Serum creatinine leads to Occurrence, Cytoplasmic vacuolization (Renal tubule)
630 Occurrence, A paroxysmal depolarizing shift leads to Occurrence, Epileptic seizure
944 Increase, Proliferation of goblet cells leads to Goblet cell hyperplasia
829 Decreased, Glomerular filtration leads to Occurrence, Kidney toxicity
830 Decreased, Renal plasma flow leads to Occurrence, Kidney toxicity
831 Decreased, Sodium reabsorption leads to Occurrence, Kidney toxicity
832 Decreased, Renal ability to dilute urine leads to Occurrence, Kidney toxicity
1676 Increase, Cytotoxicity (renal tubular cell) leads to Occurrence, Kidney toxicity
943 Occurrence, Transdifferentiation of ciliated epithelial cells leads to Occurrence, Metaplasia of goblet cells
1138 Decreased, Prostaglandin F2alpha concentration, plasma leads to Occurrence, renal ischemia
1133 Occurrence, tophi (urate) deposition leads to Occurrence, renal proximal tubular necrosis
1139 Occurrence, renal ischemia leads to Occurrence, renal proximal tubular necrosis
1160 Increased, Oxidative Stress leads to Occurrence, renal proximal tubular necrosis
1132 Increased, blood uric acid concentration leads to Occurrence, tophi (urate) deposition
942 Activation, Epidermal Growth Factor Receptor leads to Occurrence, Transdifferentiation of ciliated epithelial cells
961 Decrease, Apoptosis of ciliated epithelial cells leads to Occurrence, Transdifferentiation of ciliated epithelial cells
965 Activation, EGFR leads to Occurrence, Transdifferentiation of ciliated epithelial cells
1271 TRPA1 activation, TRPA1 Receptor leads to Opening of calcium channel, Calcium influx
1281 TRPV1 activation, TRPV1 leads to Opening of calcium channel, Calcium influx
1287 Non-neuronal production of IL-8/CXCL1, Epithelial irritation leads to Opening of calcium channel, Calcium influx
1288 Non-neuronal production of TNF, Epithelial irritation leads to Opening of calcium channel, Calcium influx
1564 Release of G Proteins leads to Opening of GIRK channels
1196 Uncarboxylated osteocalcin not incorporated into bone matrix, decreasing bone strength, Imp leads to Osteoporosis and vascular calcification, Bone deterioration
605 Overactivation, Neuronotransmitter release leads to Overactivation, muscle contraction
604 prolonged, Depolarization of neuronal membrane leads to Overactivation, Neuronotransmitter release
360 Binding of agonist, NMDARs leads to Overactivation, NMDARs
919 Binding of agonist, Ionotropic glutamate receptors leads to Overactivation, NMDARs
660 N/A, Mitochondrial dysfunction 1 leads to Overwhelmed, Mitochondrial DNA repair mechanisms
948 Peptide Oxidation leads to Oxidation, Glutathione
867 Inhibition, UROD leads to Oxidation, Uroporphyrinogen
868 Induction, CYP1A2/CYP1A5 leads to Oxidation, Uroporphyrinogen
1512 Activation of Cyp2E1 leads to Oxidative Stress
1684 N/A, Mitochondrial dysfunction 1 leads to Oxidative Stress
1689 Binding, SH/SeH proteins involved in protection against oxidative stress leads to Oxidative Stress
1766 Protection against oxidative stress, decreased leads to Oxidative Stress
1726 CYP2E1 Activation leads to Oxidative Stress in Brain
1710 Histone acetylation, increase leads to p21 (CDKN1A) expression, increase
1714 Histone deacetylase inhibition leads to p21 (CDKN1A) expression, increase
910 Degeneration of dopaminergic neurons of the nigrostriatal pathway leads to Parkinsonian motor deficits
96 Up Regulation, CYP1A1 leads to Peptide Oxidation
146 Increased, Activation and Recruitment of Hepatic macrophages (Kupffer Cells) leads to Peptide Oxidation
271 Alkylation, Protein leads to Peptide Oxidation
276 Production, Reactive oxygen species leads to Peptide Oxidation
763 Increase, Oxidative metabolism leads to Peptide Oxidation
921 Disruption, Lysosome leads to Peptide Oxidation
1234 Increase, Genes involved in fatty acid oxidation leads to Peptide Oxidation
1235 Activation, NADPH Oxidase leads to Peptide Oxidation
1241 Increase, Peroxisomal Fatty Acid Beta Oxidation of Fatty Acids leads to Peptide Oxidation
1466 Increase, Excessive ROS generation leads to Peptide Oxidation
477 Suppression, Constitutive androstane receptor, NR1l3 leads to demethylation, PPARg promoter
1423 Activation, L-FABP leads to demethylation, PPARg promoter
1372 Up Regulation, Unsaturated fatty acid leads to Perturbation of cholesterol
1375 Activation, 3-hydroxy-3-methylglutaryl-CoA reductase gene leads to Perturbation of cholesterol
1594 Foam cell formation leads to Plaque progression
1187 Increase, cilia movement leads to premature, Spawning
1210 Increased, cilia movement leads to premature, Spawning
1225 Increased, water pumping leads to premature, Spawning
1178 Increase, cilia movement leads to premature, spawning 1
1286 Oxidization of biomolecules, Lipid bilayer and cellular proteins leads to Production of nerve growth factor , Epithelial irritation
1293 Oxidation leads to Production of nerve growth factor , Epithelial irritation
1356 Differentiation of Myofibroblast leads to Production of α-smooth muscle actin
930 Bile accumulation, Pathological condition leads to Production, Reactive oxygen species
324 N/A, Unknown leads to Proliferation, Cell proliferation in the absence of cytotoxicity
1104 Promotion, SIX-1 postive basal-type progenitor cells leads to Proliferation/Clonal Expansion, aberrant basal cells
1081 relaxation, smooth muscle leads to Proliferation/Clonal Expansion, smooth muscle
603 modulation, sodium channel leads to prolonged, Depolarization of neuronal membrane
1100 Increased, cholestasis leads to prolonged, elevation of serun CCK
1110 Decreased, LH Surge from anterior pituitary leads to prolonged, estrus
158 Hyperplasia, Hyperplasia leads to Promotion, Hepatocelluar carcinoma
1083 Hypertrophy/hyperplasia, smooth muscle leads to Promotion, mesovarian leiomyomas
1093 Hyperplasia, ovarian epithelium leads to Promotion, ovarian adenomas
1094 Hyperplasia, ovarian stromal cells leads to Promotion, ovarian granular cell tumors
1103 Activation, estrogen receptor alpha leads to Promotion, SIX-1 postive basal-type progenitor cells
244 N/A, Parent compound is converted to the reactive metabolite and forms free radicals leadin leads to Propagation, Oxidative stress
1728 Lipid Peroxidation leads to Protein Adduct Formation
1629 Accumulation, Collagen leads to Pulmonary fibrosis
1708 Increased extracellular matrix deposition leads to Pulmonary fibrosis
1446 Inactivated, 5-HTR leads to Reduce expression, BDNF
973 dimerization, AHR/ARNT leads to reduced dimerization, ARNT/HIF1-alpha
1170 Blood loss and development of anemia, Impaired oxygen delivery and nutrient delivery to tis leads to Reduced fitness or even mortality, Acidosis, hypovolemic shock and organ dysfunction
347 Decreased, Calcium influx leads to BDNF, Reduced
444 T4 in neuronal tissue, Decreased leads to BDNF, Reduced
1504 TH synthesis, Decreased leads to BDNF, Reduced
974 reduced dimerization, ARNT/HIF1-alpha leads to reduced production, VEGF
673 Reduced, Spawning behavior leads to Reduced, Ability to attract spawning mates
679 Reduced, Pheromone release leads to Reduced, Ability to attract spawning mates
1031 Reduced, Posterior swim bladder inflation leads to Reduced, Anterior swim bladder inflation
1035 Decreased, Triiodothyronine (T3) in serum leads to Reduced, Anterior swim bladder inflation
1039 T4 in serum, Decreased leads to Reduced, Anterior swim bladder inflation
1040 Thyroperoxidase, Inhibition leads to Reduced, Anterior swim bladder inflation
1043 Inhibition, Deiodinase 2 leads to Reduced, Anterior swim bladder inflation
1045 Inhibition, Deiodinase 1 leads to Reduced, Anterior swim bladder inflation
577 Decreased, Hydrogen peroxide production leads to Reduced, Antiseptic incorporated in food
1451 Activation, Glucocorticoid Receptor leads to Reduced, BDNF
1511 Inactivated, 5-HTR leads to Reduced, BDNF
1522 Increased, glucocorticoid receptor activity leads to Reduced, BDNF
565 Abnormal, Roll change within caste leads to Reduced, Brood care
1561 Reduced, HSD17B4 activity leads to Reduced, fatty acid beta oxidation
587 Reduced, swimming speed leads to Reduced, feeding 1
579 Abnormal, Roll change within caste leads to Reduced, Food storage
584 Abnormal, Foraging activity and behavior leads to Reduced, Food storage
1556 NFE2/Nrf2 repression leads to Reduced, FXR activity
1552 Decreased, GABA leads to Reduced, GABA-A receptor activation
1555 Increased, RDX dose leads to Reduced, GABA-A receptor activation
690 Reduced, Prostaglandin E2 concentration, hypothalamus leads to Reduced, Gonadotropin releasing hormone, hypothalamus
1032 Reduced, Anterior swim bladder inflation leads to Reduced, Hearing
1560 Reduced, PPARalpha leads to Reduced, HSD17B4 activity
691 Reduced, Gonadotropin releasing hormone, hypothalamus leads to Reduced, Luteinizing hormone (LH), plasma
693 Reduced, Maturation inducing steroid, plasma leads to Reduced, Maturation inducing steroid receptor signalling, oocyte
692 Reduced, Luteinizing hormone (LH), plasma leads to Reduced, Maturation inducing steroid, plasma
696 Increased, cyclic adenosine monophosphate leads to Reduced, Meiotic prophase I/metaphase I transition, oocyte
1535 Decreased, mucosal blood flow leads to Reduced, mucosal defense
1538 Decreased, mucous leads to Reduced, mucosal defense
1540 Decreased, bicarbonate leads to Reduced, mucosal defense
1547 Decrease, surfactant leads to Reduced, mucosal defense
678 Reduced, Prostaglandin F2alpha concentration, plasma leads to Reduced, Pheromone release
1532 Reduced, PTGS1 function leads to Reduced, platelet aggregation
1027 Decreased, Triiodothyronine (T3) in serum leads to Reduced, Posterior swim bladder inflation
1042 Inhibition, Deiodinase 2 leads to Reduced, Posterior swim bladder inflation
1044 Inhibition, Deiodinase 1 leads to Reduced, Posterior swim bladder inflation
1559 Activated, LXR leads to Reduced, PPARalpha
354 BDNF, Reduced leads to Reduced, Presynaptic release of glutamate
689 Inhibition, Cyclooxygenase activity leads to Reduced, Prostaglandin E2 concentration, hypothalamus
671 Reduced, Prostaglandin F2alpha synthesis, ovary leads to Reduced, Prostaglandin F2alpha concentration, plasma
682 Decreased, Prostaglandin F2alpha synthesis, ovary leads to Reduced, Prostaglandin F2alpha concentration, plasma
670 Inhibition, Cyclooxygenase activity leads to Reduced, Prostaglandin F2alpha synthesis, ovary
686 Inhibition, Cyclooxygenase activity leads to Reduced, Prostaglandins, ovary
674 Reduced, Ability to attract spawning mates leads to Reduced, Reproductive Success
687 Decrease, Ovulation leads to Reduced, Reproductive Success
695 Increased, cyclic adenosine monophosphate leads to Reduced, Reproductive Success
697 Reduced, Meiotic prophase I/metaphase I transition, oocyte leads to Reduced, Reproductive Success
700 Increased, Chromosome misseggregation leads to Reduced, Reproductive Success
1557 Reduced, FXR activity leads to Reduced, SHP activity
672 Reduced, Prostaglandin F2alpha concentration, plasma leads to Reduced, Spawning behavior
595 Increased, predation leads to Reduced, survival
596 Reduced, feeding 1 leads to Reduced, survival
1028 Reduced, Posterior swim bladder inflation leads to Reduced, Swimming performance
1034 Reduced, Anterior swim bladder inflation leads to Reduced, Swimming performance
1640 Notochord malformation leads to Reduced, Swimming performance
586 Decreased, Sodium conductance 1 leads to Reduced, swimming speed
1029 Reduced, Swimming performance leads to Reduced, Young of year survival
1033 Reduced, Hearing leads to Reduced, Young of year survival
1041 Reduced, Posterior swim bladder inflation leads to Reduced, Young of year survival
395 demethylation, PPARg promoter leads to reduction in ovarian granulosa cells, Aromatase (Cyp19a1)
1637 Inhibition of lysyl oxidase leads to Reduction of collagen crosslinking
43 Decrease, Aromatase (Cyp19a1) leads to Reduction, 17beta-estradiol synthesis by ovarian granulosa cells
45 Inhibition, Aromatase leads to Reduction, 17beta-estradiol synthesis by ovarian granulosa cells
104 Up Regulation, CYP1B1 leads to Reduction, 17beta-estradiol synthesis by ovarian granulosa cells
302 Reduction, Testosterone synthesis by ovarian theca cells leads to Reduction, 17beta-estradiol synthesis by ovarian granulosa cells
396 reduction in ovarian granulosa cells, Aromatase (Cyp19a1) leads to Reduction, 17beta-estradiol synthesis by ovarian granulosa cells
801 Decreased, Aromatase (Cyp19a1) mRNA leads to Reduction, 17beta-estradiol synthesis by ovarian granulosa cells
1384 Agonism, Androgen receptor leads to Reduction, 17beta-estradiol synthesis by ovarian granulosa cells
335 Inhibition, VegfR2 leads to Reduction, Angiogenesis
136 N/A, Gap leads to Reduction, Ca and HCO3 transport to shell gland
436 Decrease, Steroidogenic acute regulatory protein (STAR) leads to Reduction, Cholesterol transport in mitochondria
437 Decrease, Translocator protein (TSPO) leads to Reduction, Cholesterol transport in mitochondria
337 Reduction, Vitellogenin accumulation into oocytes and oocyte growth/development leads to Reduction, Cumulative fecundity and spawning
544 Decrease, Ovulation leads to Reduction, Cumulative fecundity and spawning
1769 Reduction, Plasma vitellogenin concentrations leads to Reduction, Cumulative fecundity and spawning
59 Reduction, Ca and HCO3 transport to shell gland leads to Reduction, Eggshell thickness
31 Agonism, Androgen receptor leads to Reduction, Gonadotropins, circulating concentrations
666 Binding at picrotoxin site, iGABAR chloride channel leads to Reduction, Ionotropic GABA receptor chloride channel conductance
667 Reduction, Ionotropic GABA receptor chloride channel conductance leads to Reduction, Neuronal synaptic inhibition
1017 Interference, nuclear localization of NFAT leads to Reduction, NFAT/AP-1 complex formation
5 Reduction, 17beta-estradiol synthesis by ovarian granulosa cells leads to Reduction, Plasma 17beta-estradiol concentrations
1768 TH synthesis, Decreased leads to Reduction, Plasma 17beta-estradiol concentrations
315 Reduction, Vitellogenin synthesis in liver leads to Reduction, Plasma vitellogenin concentrations
1386 Reduction, Plasma 17beta-estradiol concentrations leads to Reduction, Plasma vitellogenin concentrations
95 Inhibition, Cyclooxygenase activity leads to Reduction, Prostaglandin E2 concentration
439 Reduction, Testosterone synthesis in Leydig cells leads to Reduction, testosterone level
32 Agonism, Androgen receptor leads to Reduction, Testosterone synthesis by ovarian theca cells
143 Reduction, Gonadotropins, circulating concentrations leads to Reduction, Testosterone synthesis by ovarian theca cells
399 Decrease, Translocator protein (TSPO) leads to Reduction, Testosterone synthesis in Leydig cells
438 Reduction, Cholesterol transport in mitochondria leads to Reduction, Testosterone synthesis in Leydig cells
1647 Increased apoptosis, decreased Leydig Cells leads to Reduction, Testosterone synthesis in Leydig cells
1648 Repressed expression of steroidogenic enzymes leads to Reduction, Testosterone synthesis in Leydig cells
253 Reduction, Plasma 17beta-estradiol concentrations leads to Reduction, Vitellogenin accumulation into oocytes and oocyte growth/development
255 Reduction, Plasma vitellogenin concentrations leads to Reduction, Vitellogenin accumulation into oocytes and oocyte growth/development
129 Antagonism, Estrogen receptor leads to Reduction, Vitellogenin synthesis in liver
252 Reduction, Plasma 17beta-estradiol concentrations leads to Reduction, Vitellogenin synthesis in liver
1385 Agonism, Androgen receptor leads to Reduction, Vitellogenin synthesis in liver
1514 Hepatocytotoxicity leads to Regenerative Proliferation
1080 Increased activity, beta-2 adrenergic receptor leads to relaxation, smooth muscle
1563 Mu Opioid Receptor Agonism leads to Release of G Proteins
1571 Serotonin 1A Receptor Agonism leads to Release of G Proteins
923 Peptide Oxidation leads to Release, Cytokine
924 N/A, Cell injury/death leads to Release, Cytokine
928 Bile accumulation, Pathological condition leads to Release, Cytokine
1021 Reduction, NFAT/AP-1 complex formation leads to Relief, Relief of atopic dermatitis
1646 GR Agonist, Activation leads to Repressed expression of steroidogenic enzymes
1368 Apoptosis leads to Reproductive failure
1370 Activation, TGF-beta pathway leads to Reproductive failure
1383 Defect of Embryogenesis leads to Reproductive failure
376 Covalent Binding, Protein leads to Response, Keratinocytes
1360 Activation, NADPH Oxidase leads to ROS formation
835 Activation/Proliferation, T-cells leads to sensitisation, skin
1289 Generation of novel epitopes , Antigen presentation leads to Sensitization, Immune system
1290 Leukocyte infiltration leads to Sensitization, Immune system
1498 7α-hydroxypregnenolone synthesis in the brain, decreased leads to Sexual behavior, decreased
1502 Dopamine release in the brain, decreased leads to Sexual behavior, decreased
1280 Opening of calcium channel, Calcium influx leads to SP (Substance P) release, Local increase of SP
1283 Production of nerve growth factor , Epithelial irritation leads to SP (Substance P) release, Local increase of SP
1575 Excitation, Trigeminal nerve excitation leads to SP (Substance P) release, Local increase of SP
1735 Apoptosis leads to spermatocyte depletion
1105 Proliferation/Clonal Expansion, aberrant basal cells leads to squamous metaplasia, aberrant basal cells
1023 Binding of antagonist, PPAR alpha leads to stabilization, PPAR alpha co-repressor
1254 Inhibition, Calcineurin Activity leads to Suppression, IL-2 and IL-4 production
1509 Reduction, NFAT/AP-1 complex formation leads to Suppression, IL-2 and IL-4 production
390 Decreased, Lymphocytes leads to Suppression, Immune system
387 Inhibition, Nuclear factor kappa B (NF-kB) leads to Suppression, Inflammatory cytokines
1018 Reduction, NFAT/AP-1 complex formation leads to Suppression, Suppression in mixed lymphocyte reaction (MLR)
1256 Reduction, NFAT/AP-1 complex formation leads to Suppression, Suppression of production of cytotoxic T-cells
1257 Reduction, NFAT/AP-1 complex formation leads to Suppression, Suppression of T-cell dependent antibody production
1019 Reduction, NFAT/AP-1 complex formation leads to Suppression, Suppression of T-cell dependent antibody response (TDAR)
509 Activation, AhR leads to Suppression, VLDL secretion
77 Activation, ChREBP leads to Synthesis, De Novo FA
133 Activation, FAS leads to Synthesis, De Novo FA
284 Activation, SCD-1 leads to Synthesis, De Novo FA
294 Activation, SREBP-1c leads to Synthesis, De Novo FA
1713 Apoptosis leads to testicular toxicity
1717 Histone deacetylase inhibition leads to testicular toxicity
1734 spermatocyte depletion leads to testicular toxicity
309 Thyroperoxidase, Inhibition leads to TH synthesis, Decreased
552 Inhibition, Na+/I- symporter (NIS) leads to TH synthesis, Decreased
872 Thyroidal Iodide, Decreased leads to TH synthesis, Decreased
1202 Inhibition, Pendrin leads to TH synthesis, Decreased
1203 Inhibition, Dual oxidase leads to TH synthesis, Decreased
312 T4 in serum, Decreased leads to T4 in neuronal tissue, Decreased
1718 N/A, Cell injury/death leads to Tissue resident cell activation
1276 Excitation, Trigeminal nerve excitation leads to Increased Airway Hyper-responsiveness,Cough, Dyspnea
1574 SP (Substance P) release, Local increase of SP leads to Increased Airway Hyper-responsiveness,Cough, Dyspnea
1579 Increased CGRP leads to Increased Airway Hyper-responsiveness,Cough, Dyspnea
1584 Increased NKA leads to Increased Airway Hyper-responsiveness,Cough, Dyspnea
1770 Respiratory irritability leads to Increased Airway Hyper-responsiveness,Cough, Dyspnea
1774 Irritation induced sneezing leads to Increased Airway Hyper-responsiveness,Cough, Dyspnea
1274 Opening of calcium channel, Calcium influx leads to Excitation, Trigeminal nerve excitation
1282 Oxidization of biomolecules, Lipid bilayer and cellular proteins leads to TRPA1 activation, TRPA1 Receptor
1292 Oxidation leads to TRPA1 activation, TRPA1 Receptor
343 Increased, Proliferation/Clonal Expansion of Mutant Cells (Pre-Neoplastic Lesions/Altered H leads to Tumorigenesis, Hepatocellular carcinoma
345 Formation, Pro-mutagenic DNA Adducts leads to Tumorigenesis, Hepatocellular carcinoma
346 Increased, Induced Mutations in Critical Genes leads to Tumorigenesis, Hepatocellular carcinoma
350 Increased, Clonal Expansion / Cell Proliferatin to form Pre-Neoplastic Altered Hepatic Foci leads to Tumorigenesis, Hepatocellular carcinoma
550 Clonal Expansion/Cell Proliferation, to form Altered Hepatic Foci (AHF) leads to Tumorigenesis, Hepatocellular carcinoma
1195 Calcium cannot bind to the hydroxyapatite matrix of bone, Osteocalcin and other bone protei leads to Uncarboxylated osteocalcin not incorporated into bone matrix, decreasing bone strength, Imp
1166 Hemostasis, Depletion from blood of fully functional carboxylated clotting factors leads to Under carboxylated clotting factors will not assemble on cell surfaces to form clot, Failur
1729 Protein Adduct Formation leads to Unfolded Prortein Response
1730 Oxidative Stress in Brain leads to Unfolded Prortein Response
516 Activation, LXR leads to Up Regulation, Acetyl-CoA carboxylase-1 (ACC-1)
173 Activation, LXR leads to Up Regulation, CD36
411 demethylation, PPARg promoter leads to Up Regulation, CD36
495 Activation, AhR leads to Up Regulation, CD36
529 Activation, PXR/SXR leads to Up Regulation, CD36
17 Altered regulation, AHR nuclear translocator (ARNT)-dependent pathways leads to Up Regulation, CYP1A1
19 Activation, AhR leads to Up Regulation, CYP1A1
490 Activation, LXR leads to Up Regulation, FAS
506 Activation, AhR leads to Up Regulation, LDLR (low density lipoprotein receptor)
489 Activation, SREBF1 leads to Up Regulation, SCD-1
491 Activation, LXR leads to Up Regulation, SCD-1
526 Activation, PXR/SXR leads to Up Regulation, SCD-1
1656 Activation, AhR leads to Up Regulation, SCD-1
147 Increased, Activation and Recruitment of Hepatic macrophages (Kupffer Cells) leads to Up Regulation, TGFbeta1 expression
1371 Up Regulation, SREBF2 leads to Up Regulation, Unsaturated fatty acid
698 Reduced, Maturation inducing steroid receptor signalling, oocyte leads to Upregulated, Spindle assembly checkpoint protein Mad2-oocyte
866 Accumulation, Highly carboxylated porphyrins leads to Uroporphyria
1638 Reduction of collagen crosslinking leads to Weak collagen matrix
1144 Abnormal, Foraging activity and behavior leads to Weakened, Colony
1149 Abnormal, Roll change within caste leads to Weakened, Colony
1151 Abnormal, Role change within caste leads to Weakened, Colony
1153 impaired, Hive thermoregulation leads to Weakened, Colony
1154 N/A, Mitochondrial dysfunction 1 leads to Weakened, Colony
1155 Increased, Deformed Wing Virus levels leads to Weakened, Colony